was read the article
array:24 [ "pii" => "S2173572715000636" "issn" => "21735727" "doi" => "10.1016/j.medine.2015.10.001" "estado" => "S300" "fechaPublicacion" => "2015-11-01" "aid" => "803" "copyright" => "Elsevier España, S.L.U. and SEMICYUC" "copyrightAnyo" => "2015" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Med Intensiva. 2015;39:483-504" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4803 "formatos" => array:3 [ "EPUB" => 173 "HTML" => 3297 "PDF" => 1333 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0210569115001138" "issn" => "02105691" "doi" => "10.1016/j.medin.2015.05.002" "estado" => "S300" "fechaPublicacion" => "2015-11-01" "aid" => "803" "copyright" => "Elsevier España, S.L.U. and SEMICYUC" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Med Intensiva. 2015;39:483-504" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 33440 "formatos" => array:3 [ "EPUB" => 258 "HTML" => 22536 "PDF" => 10646 ] ] "es" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Artículo especial</span>" "titulo" => "Documento multidisciplinar de consenso sobre el manejo de la hemorragia masiva (documento HEMOMAS)" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "483" "paginaFinal" => "504" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Multidisciplinary consensus document on the management of massive haemorrhage (HEMOMAS document)" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J.V. Llau, F.J. Acosta, G. Escolar, E. Fernández-Mondéjar, E. Guasch, P. Marco, P. Paniagua, J.A. Páramo, M. Quintana, P. Torrabadella" "autores" => array:10 [ 0 => array:2 [ "nombre" => "J.V." "apellidos" => "Llau" ] 1 => array:2 [ "nombre" => "F.J." "apellidos" => "Acosta" ] 2 => array:2 [ "nombre" => "G." "apellidos" => "Escolar" ] 3 => array:2 [ "nombre" => "E." "apellidos" => "Fernández-Mondéjar" ] 4 => array:2 [ "nombre" => "E." "apellidos" => "Guasch" ] 5 => array:2 [ "nombre" => "P." "apellidos" => "Marco" ] 6 => array:2 [ "nombre" => "P." "apellidos" => "Paniagua" ] 7 => array:2 [ "nombre" => "J.A." "apellidos" => "Páramo" ] 8 => array:2 [ "nombre" => "M." "apellidos" => "Quintana" ] 9 => array:2 [ "nombre" => "P." "apellidos" => "Torrabadella" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2173572715000636" "doi" => "10.1016/j.medine.2015.10.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173572715000636?idApp=WMIE" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210569115001138?idApp=WMIE" "url" => "/02105691/0000003900000008/v1_201510290041/S0210569115001138/v1_201510290041/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2173572715000624" "issn" => "21735727" "doi" => "10.1016/j.medine.2015.05.004" "estado" => "S300" "fechaPublicacion" => "2015-11-01" "aid" => "811" "copyright" => "Elsevier España, S.L.U. and SEMICYUC" "documento" => "article" "crossmark" => 1 "subdocumento" => "ssu" "cita" => "Med Intensiva. 2015;39:505-15" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 17867 "formatos" => array:3 [ "EPUB" => 217 "HTML" => 14611 "PDF" => 3039 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review</span>" "titulo" => "The role of high-flow oxygen therapy in acute respiratory failure" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "505" "paginaFinal" => "515" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Papel de la oxigenoterapia de alto flujo en la insuficiencia respiratoria aguda" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 2259 "Ancho" => 1562 "Tamanyo" => 135779 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Dilution of the administered oxygen using a low- (a) and high-flow system (b). Dark gray: oxygen; light gray: room air. During normal inspiration, the peak inspiratory flow (PIF) demand is 30–40<span class="elsevierStyleHsp" style=""></span>l/min. With the use of high-flow oxygen therapy, the administered FiO<span class="elsevierStyleInf">2</span> would equal the real FiO<span class="elsevierStyleInf">2</span>, while in the case of a low-flow system the real FiO<span class="elsevierStyleInf">2</span> would be less than the administered FiO<span class="elsevierStyleInf">2</span>.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J.R. Masclans, P. Pérez-Terán, O. Roca" "autores" => array:3 [ 0 => array:2 [ "nombre" => "J.R." "apellidos" => "Masclans" ] 1 => array:2 [ "nombre" => "P." "apellidos" => "Pérez-Terán" ] 2 => array:2 [ "nombre" => "O." "apellidos" => "Roca" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0210569115001217" "doi" => "10.1016/j.medin.2015.05.009" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210569115001217?idApp=WMIE" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173572715000624?idApp=WMIE" "url" => "/21735727/0000003900000008/v1_201511200058/S2173572715000624/v1_201511200058/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S2173572715000612" "issn" => "21735727" "doi" => "10.1016/j.medine.2014.12.001" "estado" => "S300" "fechaPublicacion" => "2015-11-01" "aid" => "757" "copyright" => "Elsevier España, S.L.U. and SEMICYUC" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Med Intensiva. 2015;39:459-66" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 6365 "formatos" => array:3 [ "EPUB" => 198 "HTML" => 5025 "PDF" => 1142 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original</span>" "titulo" => "Effects of antibiotic administration delay and inadequacy upon the survival of septic shock patients" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "459" "paginaFinal" => "466" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Efectos del retraso y la inadecuación del tratamiento antibiótico en la supervivencia de los pacientes en shock séptico" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 818 "Ancho" => 1609 "Tamanyo" => 75820 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0095" class="elsevierStyleSimplePara elsevierViewall">Relationship between delay in antibiotic administration and the inadequacy of such treatment and in-hospital mortality.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "B. Suberviola Cañas, R. Jáuregui, M.Á. Ballesteros, O. Leizaola, A. González-Castro, Á. Castellanos-Ortega" "autores" => array:6 [ 0 => array:2 [ "nombre" => "B." "apellidos" => "Suberviola Cañas" ] 1 => array:2 [ "nombre" => "R." "apellidos" => "Jáuregui" ] 2 => array:2 [ "nombre" => "M.Á." "apellidos" => "Ballesteros" ] 3 => array:2 [ "nombre" => "O." "apellidos" => "Leizaola" ] 4 => array:2 [ "nombre" => "A." "apellidos" => "González-Castro" ] 5 => array:2 [ "nombre" => "Á." "apellidos" => "Castellanos-Ortega" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0210569114002836" "doi" => "10.1016/j.medin.2014.12.006" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210569114002836?idApp=WMIE" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173572715000612?idApp=WMIE" "url" => "/21735727/0000003900000008/v1_201511200058/S2173572715000612/v1_201511200058/en/main.assets" ] "en" => array:21 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Special article</span>" "titulo" => "Multidisciplinary consensus document on the management of massive haemorrhage (HEMOMAS document)" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "483" "paginaFinal" => "504" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "J.V. Llau, F.J. Acosta, G. Escolar, E. Fernández-Mondéjar, E. Guasch, P. Marco, P. Paniagua, J.A. Páramo, M. Quintana, P. Torrabadella" "autores" => array:10 [ 0 => array:3 [ "nombre" => "J.V." "apellidos" => "Llau" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 1 => array:3 [ "nombre" => "F.J." "apellidos" => "Acosta" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "G." "apellidos" => "Escolar" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 3 => array:4 [ "nombre" => "E." "apellidos" => "Fernández-Mondéjar" "email" => array:1 [ 0 => "enrique.fernandez.mondejar.sspa@juntadeandalucia.es" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 4 => array:3 [ "nombre" => "E." "apellidos" => "Guasch" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] ] ] 5 => array:3 [ "nombre" => "P." "apellidos" => "Marco" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">f</span>" "identificador" => "aff0030" ] ] ] 6 => array:3 [ "nombre" => "P." "apellidos" => "Paniagua" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">g</span>" "identificador" => "aff0035" ] ] ] 7 => array:3 [ "nombre" => "J.A." "apellidos" => "Páramo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">h</span>" "identificador" => "aff0040" ] ] ] 8 => array:3 [ "nombre" => "M." "apellidos" => "Quintana" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">i</span>" "identificador" => "aff0045" ] ] ] 9 => array:3 [ "nombre" => "P." "apellidos" => "Torrabadella" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">j</span>" "identificador" => "aff0050" ] ] ] ] "afiliaciones" => array:10 [ 0 => array:3 [ "entidad" => "Anestesia y Reanimación, Hospital Clínico Universitario de Valencia, Valencia, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Anestesia y Reanimación, Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Hemoterapia y Hematología, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Servicio de Cuidados Críticos y Urgencias, Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitaria ibs.Granada, Granada, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Anestesia y Reanimación, Hospital Universitario La Paz, Madrid, Spain" "etiqueta" => "e" "identificador" => "aff0025" ] 5 => array:3 [ "entidad" => "Hemoterapia y Hematología, Hospital General de Alicante, Alicante, Spain" "etiqueta" => "f" "identificador" => "aff0030" ] 6 => array:3 [ "entidad" => "Anestesia y Reanimación, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain" "etiqueta" => "g" "identificador" => "aff0035" ] 7 => array:3 [ "entidad" => "Hematología y Hemoterapia, Clínica Universidad de Navarra, Pamplona, Spain" "etiqueta" => "h" "identificador" => "aff0040" ] 8 => array:3 [ "entidad" => "Medicina Intensiva, Hospital Universitario La Paz, Madrid, Spain" "etiqueta" => "i" "identificador" => "aff0045" ] 9 => array:3 [ "entidad" => "Unidad de Cuidados Intensivos, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain" "etiqueta" => "j" "identificador" => "aff0050" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Documento multidisciplinar de consenso sobre el manejo de la hemorragia masiva (documento HEMOMAS)" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Massive hemorrhage (MH) is a frequent condition caused by a range of circumstances including polytraumatism, peripartum, the perioperative period of different types of surgery, or gastrointestinal bleeding. It is commonly associated to important morbidity–mortality, conditioned to the underlying cause. In routine practice, the multidisciplinary management of MH is characterized by great variability; consensus-based recommendations therefore seem necessary in relation to the prevention, diagnosis, evaluation and application of the opportune therapeutic measures for controlling the bleeding.</p><p id="par0010" class="elsevierStylePara elsevierViewall">One of the starting points is undoubtedly the need to establish an adequate definition of MH. The existing heterogeneity in interpreting the disorder means that it is difficult to establish the true incidence of MH in the different clinical scenarios; in this respect, it is considered that MH is often underestimated in terms of both its diagnosis and importance. Likewise, despite the different protocols that have been proposed to date, there is no agreement regarding the predictive value of the diagnostic tests, the best method for quantifying blood loss, the adequate assessment of treatment response, or the efficacy and safety of the recommended bleeding control measures.</p><p id="par0015" class="elsevierStylePara elsevierViewall">Despite the efforts made in recent years to reach agreements regarding the protocols, guides and interventional algorithms referred to MH, and their diffusion, there is still an important lack of multidisciplinary consensus in our setting. The lack of scientific evidence in many of the proposed interventions, the undeniable urgency of the required treatment, and the lack of experience and specific training in the management of these situations found in some cases have pointed to the need for a consensus document, with the aim of facilitating the decision making process for all those involved in the treatment of MH. With this objective in mind, a series of experts belonging to the Spanish Society of Anesthesia and Resuscitation (<span class="elsevierStyleItalic">Sociedad Española de Anestesiología y Reanimación</span>, SEDAR), the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (<span class="elsevierStyleItalic">Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias</span>, SEMICYUC) and the Spanish Society of Thrombosis and Hemostasia (<span class="elsevierStyleItalic">Sociedad Española de Trombosis y Hemostasia</span>, SETH) decided to draft a manuscript with an eminently practical bearing, endorsed by the mentioned scientific societies. This consensus document offers the most important and appropriate recommendations in each case, extracted from the literature and applicable to MH in all its dimensions–from early diagnosis to the last step in management and control.</p><p id="par0020" class="elsevierStylePara elsevierViewall">Form the multidisciplinary development of the document, we have underscored that its diffusion and application can contribute to improve the quality, safety and sustainability of the healthcare system, attempting to unify interventional and decision criteria.</p><p id="par0025" class="elsevierStylePara elsevierViewall">As the authors of the initiative, we are convinced that the <span class="elsevierStyleItalic">“Multidisciplinary consensus document on the management of massive hemorrhage (HEMOMAS document)</span>” is an excellent tool with a permanent potential for modification and improvement, and that its usefulness will be confirmed over time, considering that Medicine is a very rapidly advancing field. The fundamental objective of our effort is to ensure that the document will be of help to all those involved in the management of MH. We hope to share our recommendations with these professionals, and to receive suggestions derived from their clinical practice.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Methodology</span><p id="par0030" class="elsevierStylePara elsevierViewall">With the scientific endorsement of the mentioned three scientific societies, a group of ten experts in anesthesia, intensive care and hematology was created, with the designation of a coordinator. These experts jointly developed the contents of the document. In the month of March 2013, a literature search was made of the Cochrane Library, Medline (PubMed) and Guiasalud databases, covering the last 10 years and using the combination of key words in the title or abstract: <span class="elsevierStyleItalic">“massive hemorrhage</span>”, “<span class="elsevierStyleItalic">massive transfusion</span>” and “<span class="elsevierStyleItalic">hemorrhagic shock</span>”. Based on the selected articles, we established the recommendations, categorizing the specific grades of recommendation and levels of evidence found. The Grades of Recommendation Assessment, Development and Evaluation (GRADE)<a class="elsevierStyleCrossRef" href="#bib1000"><span class="elsevierStyleSup">1</span></a> were used to this effect, transferring the results to an alphanumerical scale in order to improve understanding of the recommendations<a class="elsevierStyleCrossRef" href="#bib1005"><span class="elsevierStyleSup">2</span></a> (see <a class="elsevierStyleCrossRef" href="#sec0365">Supplementary material online</a>).</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Results and discussion</span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Literature search and development of recommendations</span><p id="par0035" class="elsevierStylePara elsevierViewall">The literature search, carried out in March 2013, yielded a total of 4264 articles. After defining their priority through successive reading and analysis of the title, abstract and full text articles, we selected a total of 190 publications, to which 31 further articles (recently published or identified from the literature during the document drafting process) were added.</p><p id="par0040" class="elsevierStylePara elsevierViewall">Following the literature synthesis and after application of the consensus methodology, we validated a total of 47 recommendations (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Definitions</span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Massive hemorrhage</span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">What is the definition of massive hemorrhage?</span><p id="par0045" class="elsevierStylePara elsevierViewall">The definition of MH is arbitrary and has little clinical value. However, any of the adequate definitions found in the literature can serve as a basis for implementing a specific MH management protocol. The most common definitions include the following:<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">•</span><p id="par0050" class="elsevierStylePara elsevierViewall">Blood loss of over 150<span class="elsevierStyleHsp" style=""></span>ml/min during more than 10<span class="elsevierStyleHsp" style=""></span>min.<a class="elsevierStyleCrossRef" href="#bib1010"><span class="elsevierStyleSup">3</span></a></p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">•</span><p id="par0055" class="elsevierStylePara elsevierViewall">Loss of a blood volume in 24<span class="elsevierStyleHsp" style=""></span>h.</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">•</span><p id="par0060" class="elsevierStylePara elsevierViewall">Major hemorrhage requiring the transfusion of 4 red cell concentrate units in 1<span class="elsevierStyleHsp" style=""></span>h.</p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">•</span><p id="par0065" class="elsevierStylePara elsevierViewall">Loss of 1–1.5 volemia equivalents in 24<span class="elsevierStyleHsp" style=""></span>h.<a class="elsevierStyleCrossRef" href="#bib1015"><span class="elsevierStyleSup">4</span></a></p></li><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">•</span><p id="par0070" class="elsevierStylePara elsevierViewall">Loss of 50% of volemia equivalent in 3<span class="elsevierStyleHsp" style=""></span>h.<a class="elsevierStyleCrossRef" href="#bib1020"><span class="elsevierStyleSup">5</span></a></p></li><li class="elsevierStyleListItem" id="lsti0030"><span class="elsevierStyleLabel">•</span><p id="par0075" class="elsevierStylePara elsevierViewall">Life-threatening major hemorrhage requiring massive transfusion.<a class="elsevierStyleCrossRef" href="#bib1025"><span class="elsevierStyleSup">6</span></a></p></li></ul></p><p id="par0080" class="elsevierStylePara elsevierViewall">Although all of these definitions were considered adequate and applicable to routine practice, the panel of experts agreed that the first definition is probably the best when the blood losses are quantifiable–though such quantification is not always possible.</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">What is the definition of massive transfusion?</span><p id="par0085" class="elsevierStylePara elsevierViewall">In adults, massive transfusion (MT) can be defined as the transfusion of half the body blood volume in 4<span class="elsevierStyleHsp" style=""></span>h, or of more than one such volume in 24<span class="elsevierStyleHsp" style=""></span>h (the blood volume of an adult is about 70<span class="elsevierStyleHsp" style=""></span>ml/kg).<a class="elsevierStyleCrossRef" href="#bib1025"><span class="elsevierStyleSup">6</span></a></p><p id="par0090" class="elsevierStylePara elsevierViewall">For quantification and comparison purposes, the most widely accepted definition is the administration of at least 10 red cell concentrate units in the 24<span class="elsevierStyleHsp" style=""></span>h following the start of treatment.<a class="elsevierStyleCrossRefs" href="#bib1030"><span class="elsevierStyleSup">7,8</span></a></p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">What are the most frequent causes of massive hemorrhage?</span><p id="par0095" class="elsevierStylePara elsevierViewall">No strict order in the frequency of causes of MH can be established, since it is largely dependent upon the clinical and social context involved. Nevertheless, in general it is agreed that the leading causes of MH are:<ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0035"><span class="elsevierStyleLabel">•</span><p id="par0100" class="elsevierStylePara elsevierViewall">Polytraumatism</p></li><li class="elsevierStyleListItem" id="lsti0040"><span class="elsevierStyleLabel">•</span><p id="par0105" class="elsevierStylePara elsevierViewall">Cardiovascular surgery</p></li><li class="elsevierStyleListItem" id="lsti0045"><span class="elsevierStyleLabel">•</span><p id="par0110" class="elsevierStylePara elsevierViewall">Postpartum hemorrhage</p></li><li class="elsevierStyleListItem" id="lsti0050"><span class="elsevierStyleLabel">•</span><p id="par0115" class="elsevierStylePara elsevierViewall">Gastrointestinal bleeding</p></li><li class="elsevierStyleListItem" id="lsti0055"><span class="elsevierStyleLabel">•</span><p id="par0120" class="elsevierStylePara elsevierViewall">Hepatobiliary surgery</p></li></ul></p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Scales for the prediction of massive transfusion and quantification of massive hemorrhage</span><p id="par0125" class="elsevierStylePara elsevierViewall">It is necessary to identify patients who may suffer MH, based on the use of predictive scales. Different studies, mainly in the context of polytrauma patients, have developed and validated a number of systems and algorithms<a class="elsevierStyleCrossRefs" href="#bib1040"><span class="elsevierStyleSup">9–13</span></a> that facilitate such identification, particularly in the early stages of bleeding. In general, the more sophisticated systems, involving a larger number of variables, are better than the simpler designs–though prospective evaluations are still needed in order to improve the prediction process and further develop the existing scales.</p><p id="par0130" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 1</span></span><a class="elsevierStyleCrossRefs" href="#bib1040"><span class="elsevierStyleSup">9,13–22</span></a>. <span class="elsevierStyleItalic">In evaluating the extent and/or severity of hemorrhage, clinical assessment (mechanism of trauma, anatomical characteristics and initial response) and the application of massive transfusion prediction scales such as the</span> Trauma-Associated Severe Hemorrhage <span class="elsevierStyleItalic">(TASH) are important (2C).</span></p></span></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Massive transfusion</span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">What clinical and/or biological parameters should activate the intervention protocol in the event of massive hemorrhage?</span><p id="par0135" class="elsevierStylePara elsevierViewall">The rapid identification of patients at risk of suffering MH and therefore of requiring MT is essential for immediate activation of the corresponding massive transfusion protocols (MTPs).<a class="elsevierStyleCrossRef" href="#bib1110"><span class="elsevierStyleSup">23</span></a> A number of clinical scales and laboratory test parameters have been developed to objectively identify such patients.</p><p id="par0140" class="elsevierStylePara elsevierViewall">Regarding the clinical scales, the TASH score<a class="elsevierStyleCrossRef" href="#bib1060"><span class="elsevierStyleSup">13</span></a> offers the greatest sensitivity (84.4%) and specificity<a class="elsevierStyleCrossRef" href="#bib1110"><span class="elsevierStyleSup">23</span></a> (78.4%). Another scale that is very widely used, since it does not involve laboratory test data that may delay the decision to activate the MTP, is the Assessment of Blood Consumption (ABC)<a class="elsevierStyleCrossRef" href="#bib1115"><span class="elsevierStyleSup">24</span></a> (see <a class="elsevierStyleCrossRef" href="#sec0365">Supplementary material online</a>).</p><p id="par0145" class="elsevierStylePara elsevierViewall">Compatible blood transfusion of patients with severe trauma upon admission to the emergency service has been shown to be an independent predictor of the need for early MT (>10 red cell concentrate units [RCC] in 6<span class="elsevierStyleHsp" style=""></span>h), not only of blood but also of plasma and platelets.<a class="elsevierStyleCrossRef" href="#bib1120"><span class="elsevierStyleSup">25</span></a></p><p id="par0150" class="elsevierStylePara elsevierViewall">Regarding the laboratory test parameters upon arrival in hospital, a base deficit of >6<span class="elsevierStyleHsp" style=""></span>mEq/l, plasma hemoglobin<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>11<span class="elsevierStyleHsp" style=""></span>g/dl and pH<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>7.25 have been shown to significantly increase the risk of MT, and are included in several of the predictive scales.</p><p id="par0155" class="elsevierStylePara elsevierViewall">In the study published by Davenport et al.<a class="elsevierStyleCrossRef" href="#bib1125"><span class="elsevierStyleSup">26</span></a>, involving 300 trauma patients, rotational thromboelastometry was used to identify acute coagulopathy and to predict the need for MT. A clot size after 5<span class="elsevierStyleHsp" style=""></span>min of ≤35<span class="elsevierStyleHsp" style=""></span>mm detected 71% of the patients who required MT, versus 43% who were detected by a prothrombin time of >1.2–with the added advantage that identification is established very quickly.</p><p id="par0160" class="elsevierStylePara elsevierViewall">Other authors have reported similar results with both rotational thromboelastometry<a class="elsevierStyleCrossRef" href="#bib1130"><span class="elsevierStyleSup">27</span></a> and thromboelastography (TEG).<a class="elsevierStyleCrossRef" href="#bib1135"><span class="elsevierStyleSup">28</span></a></p><p id="par0165" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 2</span></span><a class="elsevierStyleCrossRef" href="#bib1065"><span class="elsevierStyleSup">14</span></a>. <span class="elsevierStyleItalic">For the early identification of trauma patients who may benefit from the activation of a massive transfusion protocol it is advisable to use TASH (cutoff score 15), preferably associated to the decrease in clot firmness in rotational thromboelastometry or TEG, if available (2C).</span></p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Have the massive transfusion protocols been shown to improve patient survival?</span><p id="par0170" class="elsevierStylePara elsevierViewall">The use of a MTP has been shown to reduce both patient mortality and the need for blood product (BP) transfusions.<a class="elsevierStyleCrossRefs" href="#bib1140"><span class="elsevierStyleSup">29–31</span></a> The mechanisms underlying such improvement appear to be the administration of plasma and platelets in large proportions in relation to the red cell concentrates (RCC) in patients at high risk of requiring MT, as well as promptness in the start of transfusion,<a class="elsevierStyleCrossRef" href="#bib1155"><span class="elsevierStyleSup">32</span></a> thereby allowing early management of the coagulopathy, earlier bleeding arrest, and a reduction of transfused blood products.</p><p id="par0175" class="elsevierStylePara elsevierViewall">Borgman et al.<a class="elsevierStyleCrossRef" href="#bib1155"><span class="elsevierStyleSup">32</span></a>, in a multicenter retrospective study, showed the use of high plasma/RCC proportions (>1:2) in trauma patients at high risk of requiring MT (TASH score<span class="elsevierStyleHsp" style=""></span>≥<span class="elsevierStyleHsp" style=""></span>15) to be significantly correlated to improved survival (OR: 2.5 [1.6–4]). However, in patients at a lesser risk of requiring MT (TASH score<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>15), the use of such high proportions did not improve survival and significantly increased the risk of multiorgan failure (47% vs 38%).</p><p id="par0180" class="elsevierStylePara elsevierViewall">Riskin et al.<a class="elsevierStyleCrossRef" href="#bib1160"><span class="elsevierStyleSup">33</span></a>, on evaluating mortality two years before and after the adoption of an MTP in trauma patients, recorded a significant decrease in mortality (45% vs 19%) after introduction of the protocol. In this study there were no significant alterations in either the proportionality or the total transfused volume of the blood products used in both groups. The main difference, to which the decrease in mortality after introduction of the MTP was attributed, was the promptness of the start of transfusion (the minutes taken to start transfusion of the specific blood group), with decreases of 39%, 33% and 42% for RCC, plasma and platelets, respectively.</p><p id="par0185" class="elsevierStylePara elsevierViewall">Although the improvements in patient survival observed by most groups after the introduction of an MTP have been evidenced particularly in polytraumatized patients, other massive bleeding scenarios in which coagulopathy is suspected and bleeding control proves difficult can also derive benefit. However, no studies have produced sufficient evidence as to which protocol is best for improving patient survival.</p><p id="par0190" class="elsevierStylePara elsevierViewall">On the other hand, before drawing conclusions on the efficacy of MTPs in reference to patient prognosis, due consideration is required of the analysis of both the protocol itself and of the degree of compliance.<a class="elsevierStyleCrossRefs" href="#bib1165"><span class="elsevierStyleSup">34,35</span></a></p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">What criteria should be used to construct, implement and monitor a massive transfusion protocol?</span><p id="par0195" class="elsevierStylePara elsevierViewall">Massive transfusion protocols must offer a coordinated and efficient decision making process capable of ensuring the optimum management of MT.<a class="elsevierStyleCrossRef" href="#bib1175"><span class="elsevierStyleSup">36</span></a> Enticott et al.<a class="elsevierStyleCrossRef" href="#bib1180"><span class="elsevierStyleSup">37</span></a>, in a systematic review, summarized the points considered crucial for guiding the design and implementation of an MTP. The steps considered necessary for such implementation are described in the supplementary material online.<a class="elsevierStyleCrossRefs" href="#bib1140"><span class="elsevierStyleSup">29–38</span></a></p><p id="par0200" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 3</span></span><a class="elsevierStyleCrossRef" href="#bib1180"><span class="elsevierStyleSup">37</span></a>. <span class="elsevierStyleItalic">Institutions should develop massive transfusion protocols coordinated on a multidisciplinary basis, with management algorithms fundamented upon scientific evidence. Likewise, informative and training campaigns are recommended, targeted to the teams involved, with periodic evaluation of compliance and effectiveness and compliance (C).</span></p></span></span></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">General interventions</span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Clinical assessment of hemorrhage</span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">What are the essential aspects in the initial clinical assessment of hemorrhage?</span><p id="par0205" class="elsevierStylePara elsevierViewall">In trauma patients we should sequentially evaluate systolic blood pressure (SBP), heart rate (HR) and respiratory frequency (RF), and calculate the shock index (SI<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>HR/SBP) recorded at the site of the accident and at the time of patient arrival in hospital. The differences between the measurements, referred to as ΔSBP and ΔHR, offer good prognostic discrimination capacity, though ΔSI is superior in predicting mortality after 48<span class="elsevierStyleHsp" style=""></span>h in patients with moderate injuries, and is therefore of greater help in deciding treatment.<a class="elsevierStyleCrossRefs" href="#bib1190"><span class="elsevierStyleSup">39–42</span></a></p><p id="par0210" class="elsevierStylePara elsevierViewall">The Triage Revised Trauma Score (T-RTS), developed for the in-ambulance identification of those trauma patients who may benefit from admission to a specialized hospital, does not require summing of the coded values, is easier to apply than the Trauma Score (TS), and has been shown to be substantially more useful from the prognostic perspective than the TS.</p><p id="par0215" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 4</span></span><a class="elsevierStyleCrossRefs" href="#bib1210"><span class="elsevierStyleSup">43–45</span></a>. <span class="elsevierStyleItalic">The initial assessment should be based on the case history and anamnesis (if possible), and on the sequential determination of BP, HR and SI. The determination of base excess and lactate in arterial blood in these patients may be of help in assessing the more serious cases, fundamentally in the context of polytraumatism (2C).</span></p></span><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">How should the extent of hemorrhage be evaluated?</span><p id="par0220" class="elsevierStylePara elsevierViewall">Although the Advanced Trauma Life Support (ATLS) scale was first described over 20 years ago by the American College of Surgeons for estimating blood loss and defining treatment–including the need or not for immediate surgical control–it remains a very useful tool. Depending on the blood volume lost, the ATLS is classified from grade I to grade IV according to the observed clinical consequences.<a class="elsevierStyleCrossRef" href="#bib1105"><span class="elsevierStyleSup">22</span></a> This classification system is useful for stratifying the early manifestations and physiopathological signs related to the loss of blood (see <a class="elsevierStyleCrossRef" href="#sec0365">Supplementary material online</a>).</p><p id="par0225" class="elsevierStylePara elsevierViewall">In addition to the above, increasingly frequent use is made of other scales for stratifying the severity of hemorrhage, such as the Triage Revised Trauma Score (T-RTS), which includes assessment of the Glasgow Coma Score (GCS), SBP and RF. In addition, the ROPE index (pulse rate over pressure evaluation) (HR divided by pulse pressure [PP, defined as the difference between SBP and the diastolic blood pressure (DBP)]; HR/PP) can be of help in detecting occult bleeding or patients at risk of suffering hemorrhagic shock. Different alternatives have been recommended for improving the discriminative capacity of the traditional vital signs (SBP, HR, RF and SI):<ul class="elsevierStyleList" id="lis0015"><li class="elsevierStyleListItem" id="lsti0060"><span class="elsevierStyleLabel">•</span><p id="par0230" class="elsevierStylePara elsevierViewall">The modified SI (MSI), corresponding to the ratio between HR and mean blood pressure (MBP), where MBP<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>([DBP<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>2]<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>SBP)/3.<a class="elsevierStyleCrossRef" href="#bib1105"><span class="elsevierStyleSup">22</span></a></p></li><li class="elsevierStyleListItem" id="lsti0065"><span class="elsevierStyleLabel">•</span><p id="par0235" class="elsevierStylePara elsevierViewall">The age-modified SI (ASI): ASI<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>SI<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>age.<a class="elsevierStyleCrossRef" href="#bib1225"><span class="elsevierStyleSup">46</span></a></p></li><li class="elsevierStyleListItem" id="lsti0070"><span class="elsevierStyleLabel">•</span><p id="par0240" class="elsevierStylePara elsevierViewall">The relation of HR to age, SBP/age (SBP/A), maximum HR for the age (MHR [mean heart rate]<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>220<span class="elsevierStyleHsp" style=""></span>−<span class="elsevierStyleHsp" style=""></span>age)<span class="elsevierStyleHsp" style=""></span>−<span class="elsevierStyleHsp" style=""></span>HR, and HR/MHR.<a class="elsevierStyleCrossRef" href="#bib1230"><span class="elsevierStyleSup">47</span></a></p></li></ul></p><p id="par0245" class="elsevierStylePara elsevierViewall">The classification of hypovolemic shock based on the base deficit (BD) may be superior to the current ATLS for identifying the presence of hypovolemic shock, for adequately stratifying risk in bleeding patients, and for defining the need for blood product transfusions.<a class="elsevierStyleCrossRef" href="#bib1235"><span class="elsevierStyleSup">48</span></a></p><p id="par0250" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 5</span></span><a class="elsevierStyleCrossRefs" href="#bib1190"><span class="elsevierStyleSup">39–41,49</span></a>. <span class="elsevierStyleItalic">The ATLS hemorrhagic shock classification for assessing the extent of hemorrhage remains valid, thanks to its quick application, accessibility and the lack of laboratory test requirements (B).</span></p><p id="par0255" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 6</span></span><a class="elsevierStyleCrossRefs" href="#bib1195"><span class="elsevierStyleSup">40,49–51</span></a>. <span class="elsevierStyleItalic">For evaluating the extent of hemorrhage in the pre-hospital setting, it is advisable to use the T-RTS classification (</span>Glasgow Coma Score <span class="elsevierStyleItalic">[GCS], SBP and RF) versus the TS, since it is easier to use and has demonstrated greater assessment capacity (C).</span></p></span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">What is the lethal triad and how does it influence the outcome of these patients?</span><p id="par0260" class="elsevierStylePara elsevierViewall">The concurrence in patients with MH of hypothermia, acidosis and coagulopathy (lethal triad) worsens the prognosis.<a class="elsevierStyleCrossRefs" href="#bib1245"><span class="elsevierStyleSup">50,52,53</span></a> More recently, hypoxia and the hyperglycemia have been added as factors that also worsen the prognosis.<a class="elsevierStyleCrossRef" href="#bib1265"><span class="elsevierStyleSup">54</span></a></p></span></span><span id="sec0100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Management of hypothermia</span><span id="sec0105" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">What is the temperature threshold beyond which the prognosis of patients with massive hemorrhage worsens?</span><p id="par0265" class="elsevierStylePara elsevierViewall">Hypothermia, defined as a core temperature of <35<span class="elsevierStyleHsp" style=""></span>°C, is often observed in patients with hemorrhagic shock who require MT, and is associated to different complications such as:<ul class="elsevierStyleList" id="lis0020"><li class="elsevierStyleListItem" id="lsti0075"><span class="elsevierStyleLabel">•</span><p id="par0270" class="elsevierStylePara elsevierViewall">Diminished liver metabolism</p></li><li class="elsevierStyleListItem" id="lsti0080"><span class="elsevierStyleLabel">•</span><p id="par0275" class="elsevierStylePara elsevierViewall">Lowered production of coagulation factors</p></li><li class="elsevierStyleListItem" id="lsti0085"><span class="elsevierStyleLabel">•</span><p id="par0280" class="elsevierStylePara elsevierViewall">Platelet dysfunction</p></li><li class="elsevierStyleListItem" id="lsti0090"><span class="elsevierStyleLabel">•</span><p id="par0285" class="elsevierStylePara elsevierViewall">Inhibition of the enzyme reactions of the coagulation cascade</p></li></ul></p><p id="par0290" class="elsevierStylePara elsevierViewall">Hypothermia is thus associated to increased bleeding, a greater need for transfusions, and increased mortality. In trauma patients, temperatures of under 35<span class="elsevierStyleHsp" style=""></span>°C upon arrival in hospital are associated to an increased mortality risk,<a class="elsevierStyleCrossRef" href="#bib1270"><span class="elsevierStyleSup">55</span></a> and this risk moreover increases as the temperature decreases further.<a class="elsevierStyleCrossRef" href="#bib1275"><span class="elsevierStyleSup">56</span></a></p><p id="par0295" class="elsevierStylePara elsevierViewall">In patients with MH it is therefore essential to adopt measures as quickly as possible for avoiding heat loss and for warming the patient (see <a class="elsevierStyleCrossRef" href="#sec0365">Supplementary material</a>). Although there is not enough evidence to recommend a concrete warming system in the context of MH, the data referred to fluid warming support the recommendation of warming all fluids administered during MT. In this regard, the systems based on countercurrent technology have been shown to be the most effective option for warming blood when the infusion rates are high.<a class="elsevierStyleCrossRef" href="#bib1280"><span class="elsevierStyleSup">57</span></a> Extracorporeal warming systems should be considered in cases of severe hypothermia and a high risk of cardiac arrest, since they significantly shorten the time needed to warm the patient. Such systems are not without complications, however, particularly in relation to the vascular accesses.<a class="elsevierStyleCrossRef" href="#bib1285"><span class="elsevierStyleSup">58</span></a></p><p id="par0300" class="elsevierStylePara elsevierViewall">For each degree centigrade decrease in temperature there is a 10% decrease in coagulation factor activity<a class="elsevierStyleCrossRef" href="#bib1290"><span class="elsevierStyleSup">59</span></a> and a 15% drop in the production of thromboxane B2, and thus in platelet aggregation.<a class="elsevierStyleCrossRef" href="#bib1295"><span class="elsevierStyleSup">60</span></a> Below 33<span class="elsevierStyleHsp" style=""></span>°C, the decrease in enzyme reactions of the coagulation cascade significantly blocks coagulation factor activity.<a class="elsevierStyleCrossRef" href="#bib1300"><span class="elsevierStyleSup">61</span></a></p><p id="par0305" class="elsevierStylePara elsevierViewall">Jurkovich et al.<a class="elsevierStyleCrossRef" href="#bib1275"><span class="elsevierStyleSup">56</span></a>, in a retrospective analysis of 71 adults with severe trauma, found that although the mortality rate for a temperature of 34<span class="elsevierStyleHsp" style=""></span>°C or higher was 7%, this figure increased to 40% in the case of temperatures under 34<span class="elsevierStyleHsp" style=""></span>°C, 69% for temperatures under 33<span class="elsevierStyleHsp" style=""></span>°C, and 100% for temperatures under 32<span class="elsevierStyleHsp" style=""></span>°C. In bleeding medical and surgical patients, temperatures of under 35<span class="elsevierStyleHsp" style=""></span>°C are associated to increased blood loss.<a class="elsevierStyleCrossRef" href="#bib1305"><span class="elsevierStyleSup">62</span></a></p><p id="par0310" class="elsevierStylePara elsevierViewall">In a retrospective analysis of over 38,000 patients, Wang et al.<a class="elsevierStyleCrossRef" href="#bib1270"><span class="elsevierStyleSup">55</span></a> found hypothermia at the time of admission to hospital in trauma patients to increase the mortality risk (OR: 4.04; 95% CI: 3.34–4.89); similar results have been recorded in patients with isolated brain injuries (OR; 3.14; 95% CI: 2.12–4.67).</p><p id="par0315" class="elsevierStylePara elsevierViewall">Reynolds et al.<a class="elsevierStyleCrossRef" href="#bib1310"><span class="elsevierStyleSup">63</span></a>, in a prospective, multicenter cohort study of trauma patients with hemorrhagic shock, found the mean temperature in the first 24<span class="elsevierStyleHsp" style=""></span>h after trauma to be under 34<span class="elsevierStyleHsp" style=""></span>°C in 34% of the patients, and this temperature was moreover identified as an independent mortality risk factor in individuals receiving low plasma/red cell concentrate ratios, but not in those receiving high ratios.</p><p id="par0320" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 7</span></span><a class="elsevierStyleCrossRefs" href="#bib1270"><span class="elsevierStyleSup">55,56,59–64</span></a>. <span class="elsevierStyleItalic">In patients with massive hemorrhage, it is advisable to quickly adopt measures for avoiding heat loss and hypothermia, keeping the core temperature above 35<span class="elsevierStyleHsp" style=""></span></span>°C <span class="elsevierStyleItalic">(1B). Among the measures for avoiding hypothermia, rapid infusion warming systems are recommended for all fluids administered during massive transfusion, with the consideration of extracorporeal warming systems in patients with severe hypothermia and a high risk of cardiac arrest (2C).</span></p></span></span><span id="sec0110" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Volume replacement</span><span id="sec0115" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">What is the initial fluid of choice in patients with massive hemorrhage?</span><p id="par0325" class="elsevierStylePara elsevierViewall">In clinical practice, patients with severe hemorrhage and hypotension are administered intravenous fluids on an early basis. Preferably isotonic crystalloids are advised, avoiding hypotonic solutions such as Ringer lactate.</p><p id="par0330" class="elsevierStylePara elsevierViewall">Among the isotonic crystalloids, balanced formulations in which the chloride levels are within the physiological limits (96–106<span class="elsevierStyleHsp" style=""></span>mEq/l) is recommended.<a class="elsevierStyleCrossRef" href="#bib1320"><span class="elsevierStyleSup">65</span></a></p><p id="par0335" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 8</span></span><a class="elsevierStyleCrossRef" href="#bib1200"><span class="elsevierStyleSup">41</span></a>. <span class="elsevierStyleItalic">Early fluid therapy is recommended in patients with severe hemorrhage and hypotension, preferably using isotonic crystalloids instead of colloids (1A).</span></p><p id="par0340" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 9</span></span><a class="elsevierStyleCrossRef" href="#bib1200"><span class="elsevierStyleSup">41</span></a>. <span class="elsevierStyleItalic">It is advisable to avoid hypotonic crystalloid solutions such as Ringer lactate in patients with severe traumatic brain injury (1C).</span></p><p id="par0345" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 10</span></span><a class="elsevierStyleCrossRefs" href="#bib1200"><span class="elsevierStyleSup">41,65–69</span></a>. <span class="elsevierStyleItalic">The administration of hypertonic solutions should be evaluated in patients with severe traumatic brain injury (2B) and in patients with penetrating trunk injuries (2C).</span></p></span><span id="sec0120" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0140">What role do colloids play?</span><p id="par0350" class="elsevierStylePara elsevierViewall">The role of colloids in volume expansion in patients with MH is the subject of controversy and debate. The administration of certain colloids (hydroxyethyl starch [HES]) recently has been associated to kidney damage and to increased mortality in septic patients, though not in the context of administration as volume replacement strategy in hemorrhagic patients. In order to limit the adverse effects, if HES is used, it is advisable not to exceed a dose of 33–50<span class="elsevierStyleHsp" style=""></span>ml/kg in 24<span class="elsevierStyleHsp" style=""></span>h, depending on the type of starch, and renal function should be monitored during 90 days.<a class="elsevierStyleCrossRef" href="#bib1330"><span class="elsevierStyleSup">67</span></a></p><p id="par0355" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 11</span></span><a class="elsevierStyleCrossRefs" href="#bib1200"><span class="elsevierStyleSup">41,67</span></a>. <span class="elsevierStyleItalic">If the clinician decides to administer colloids, it is advisable to use a dose within the limits established for each solution and patient (1B).</span></p></span><span id="sec0125" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0145">At what point during massive hemorrhage should blood products be considered?</span><p id="par0360" class="elsevierStylePara elsevierViewall">The administration of blood products should be considered in the basic management of MH.</p><p id="par0365" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 12</span></span><a class="elsevierStyleCrossRefs" href="#bib1200"><span class="elsevierStyleSup">41,70,71</span></a>. <span class="elsevierStyleItalic">In patients with MH, the early administration of blood products (including RCC, fresh plasma [FP], platelets and fibrinogen) is advised, along with simultaneous correction of the hypovolemia (1B).</span></p></span><span id="sec0130" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0150">What are the criteria and/or parameters guiding volume replacement?</span><p id="par0370" class="elsevierStylePara elsevierViewall">In addition to controlling the cause of hemorrhage, most studies recommend moderately restricted volume support, adopting the concept of hypotensive resuscitation if necessary, except in cases of severe traumatic brain injury.</p><p id="par0375" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 13</span></span><a class="elsevierStyleCrossRefs" href="#bib1200"><span class="elsevierStyleSup">41,72</span></a>. <span class="elsevierStyleItalic">It is advisable for initial fluid replacement in patients with MH to be based on the estimated blood loss and hemodynamic response to fluid administration. The application of a “hypotensive resuscitation strategy” is recommended until the cause of bleeding has been controlled, provided the patient does not suffer traumatic brain injury (2C).</span></p></span></span><span id="sec0135" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0155">Hypotensive resuscitation</span><span id="sec0140" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0160">Situations for the application of hypotensive resuscitation</span><p id="par0380" class="elsevierStylePara elsevierViewall">Volume replacement and BP restoration traditionally have been considered essential objectives in the management of trauma patients with hemorrhagic shock, and massive volume administration is needed in this respect. The normalization of BP without control of the bleeding source may further increase bleeding and therefore also result in greater fluid therapy needs–with an increased risk of coagulopathy, hypothermia and other complications which in turn contribute to worsen bleeding. This vicious circle can worsen the patient prognosis.</p><p id="par0385" class="elsevierStylePara elsevierViewall">In recent years, and in the absence of traumatic brain injury (TBI), this strategy has shifted toward more conservative positions (so-called “hypotensive resuscitation”) that aim to ensure critical perfusion of vital organs for a short period of time, without affecting their function, and until the cause of bleeding has been identified and controlled. In penetrating trauma, the adoption of a conservative fluid therapy strategy has been shown to be effective,<a class="elsevierStyleCrossRef" href="#bib1360"><span class="elsevierStyleSup">73</span></a> and although there is less supporting evidence in the case of closed trauma, a number of studies suggest that it may also be useful in this scenario.<a class="elsevierStyleCrossRefs" href="#bib1355"><span class="elsevierStyleSup">72,74–76</span></a></p><p id="par0390" class="elsevierStylePara elsevierViewall">It is currently considered that in patients without TBI, the application of hypotensive resuscitation is advisable in situations of trauma with hemorrhagic shock until the source of bleeding has been controlled.<a class="elsevierStyleCrossRef" href="#bib1200"><span class="elsevierStyleSup">41</span></a></p><p id="par0395" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 14</span></span><a class="elsevierStyleCrossRefs" href="#bib1200"><span class="elsevierStyleSup">41,72–76</span></a>. <span class="elsevierStyleItalic">In trauma patients with hemorrhage and hypotension, and without traumatic brain injury, a systolic blood pressure target of between 80 and 90</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mmHg is recommended until the cause of bleeding has been controlled (1C).</span></p><p id="par0400" class="elsevierStylePara elsevierViewall">In patients with TBI, the presence of hypotension is associated to increased mortality and a poorer functional outcome.<a class="elsevierStyleCrossRefs" href="#bib1380"><span class="elsevierStyleSup">77,78</span></a> Therefore, in cases of severe TBI, it is advisable to maintain a SBP of at least 110<span class="elsevierStyleHsp" style=""></span>mmHg, or a MBP of at least 80<span class="elsevierStyleHsp" style=""></span>mmHg.<a class="elsevierStyleCrossRef" href="#bib1200"><span class="elsevierStyleSup">41</span></a></p><p id="par0405" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 15</span></span><a class="elsevierStyleCrossRefs" href="#bib1200"><span class="elsevierStyleSup">41,77,78</span></a>. <span class="elsevierStyleItalic">In trauma patients with severe TBI it is advisable to maintain a systolic blood pressure of at least 110</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mmHg or a mean blood pressure of at least 80</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mmHg (1C).</span></p></span><span id="sec0145" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0165">When should vasopressors be used in the context of massive hemorrhage?</span><p id="par0410" class="elsevierStylePara elsevierViewall">In some cases, volume replacement alone is not enough to correct the hemodynamic situation. In such cases the risk of hypoperfusion of vital organs is high, and the use of vasoactive drugs can be decided to help revert the situation. The use of vasopressors is not without controversy, however, and one study has suggested that their administration in the first 12<span class="elsevierStyleHsp" style=""></span>h is associated to a mortality increase of almost 80%.<a class="elsevierStyleCrossRef" href="#bib1390"><span class="elsevierStyleSup">79</span></a> Nevertheless, this study has been criticized due to methodological reasons, and it is presently considered that if the patient fails to respond to fluid therapy, vasopressors can be used to restore the perfusion of vital organs.<a class="elsevierStyleCrossRef" href="#bib1200"><span class="elsevierStyleSup">41</span></a></p><p id="par0415" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 16</span></span><a class="elsevierStyleCrossRefs" href="#bib1200"><span class="elsevierStyleSup">41,79</span></a>. <span class="elsevierStyleItalic">It is suggested that the use of vasopressors such as epinephrine or norepinephrine may be an option for maintaining blood pressure in the absence of an adequate response to fluid therapy (2C).</span></p></span></span><span id="sec0150" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0170">Damage containment surgery</span><span id="sec0155" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0175">Under what circumstances should damage containment surgery be considered?</span><p id="par0420" class="elsevierStylePara elsevierViewall">The concept of damage containment surgery refers to surgery of short duration, designed to control situations that cannot be postponed in critical patients with scant physiological reserves. These patients often have hemodynamic problems and uncontrolled bleeding, with coagulation disorders and perfusion alterations with metabolic acidosis and/or hypothermia. Such cases generally involve abdominopelvic injuries, though the same concept can be extended to patients with similar characteristics involving other types of injuries requiring urgent surgery. After emergency control has been achieved, the patient is stabilized in the Intensive Care Unit (ICU), and definitive surgical treatment is provided at a later stage. A recent Cochrane review<a class="elsevierStyleCrossRef" href="#bib1395"><span class="elsevierStyleSup">80</span></a> acknowledges that no randomized studies have analyzed the efficacy of this strategy, though a series of retrospective studies confirm its usefulness,<a class="elsevierStyleCrossRefs" href="#bib1400"><span class="elsevierStyleSup">81–83</span></a> and the indication of damage containment surgery is currently contemplated by some treatment guides.<a class="elsevierStyleCrossRef" href="#bib1200"><span class="elsevierStyleSup">41</span></a></p><p id="par0425" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 17</span></span><a class="elsevierStyleCrossRefs" href="#bib1200"><span class="elsevierStyleSup">41,80–83</span></a>. <span class="elsevierStyleItalic">Application of the concept of damage containment surgery is recommended in trauma patients requiring surgical control of their injuries and who present coagulopathy with incoercible bleeding accompanied by acidosis and/or hypothermia. Likewise, this strategy should be used in the case of anatomically very complex injuries or injuries of difficult access and which require prolonged surgical times (1B).</span></p></span></span></span><span id="sec0160" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0180">Monitoring</span><span id="sec0165" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0185">Volume monitoring</span><span id="sec0170" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0190">What is the best method for the continuous monitoring of patient response to volume expansion?</span><p id="par0430" class="elsevierStylePara elsevierViewall">Volume expansion is the first measure in the management of MH. However, the excess of fluids can have harmful effects.<a class="elsevierStyleCrossRef" href="#bib1415"><span class="elsevierStyleSup">84</span></a> Although the determination of intravascular volume is one of the most difficult challenges in clinical practice, it is essential to optimize this volume through reliable predictors of patient response to fluids. A number of static and dynamic hemodynamic variables are available for this purpose.</p><p id="par0435" class="elsevierStylePara elsevierViewall">It has been shown that central venous pressure is of little predictive value in determining the hemodynamic response to volume loading.<a class="elsevierStyleCrossRefs" href="#bib1420"><span class="elsevierStyleSup">85,86</span></a> Other investigated static variables such as pulmonary capillary pressure or global end-diastolic volume likewise have not demonstrated greater predictive efficacy.<a class="elsevierStyleCrossRef" href="#bib1430"><span class="elsevierStyleSup">87</span></a></p><p id="par0440" class="elsevierStylePara elsevierViewall">The gold standard for monitoring the response to fluid loading is the continuous monitoring of cardiac output.<a class="elsevierStyleCrossRef" href="#bib1435"><span class="elsevierStyleSup">88</span></a> The absence of an increase in cardiac output in response to volume loading indicates that the plateau of the cardiovascular function curve has been reached. This in turn advises great caution in the administration of fluids, in order to prevent venous congestion.<a class="elsevierStyleCrossRef" href="#bib1440"><span class="elsevierStyleSup">89</span></a></p><p id="par0445" class="elsevierStylePara elsevierViewall">In place of static hemodynamic variables, the recommendation is to use dynamic indicators which allow us to assess preload with a view to predicting the response to fluids in patients with controlled mechanical ventilation and a normal cardiac rhythm–though in patients with severe hypovolemia due to evident bleeding, initial fluid loading to assess the response is not necessary.<a class="elsevierStyleCrossRef" href="#bib1445"><span class="elsevierStyleSup">90</span></a> The most widely used dynamic variables and with the greatest predictive value have been found to be stroke (systolic) volume variation (SVV) and pulse pressure variation (PPV).<a class="elsevierStyleCrossRefs" href="#bib1450"><span class="elsevierStyleSup">91–94</span></a> Starting the sequential evaluation of cardiac function with echocardiography in shock patients, before resorting to more invasive techniques, has also been suggested.<a class="elsevierStyleCrossRef" href="#bib1445"><span class="elsevierStyleSup">90</span></a></p><p id="par0450" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 18</span></span><a class="elsevierStyleCrossRefs" href="#bib1465"><span class="elsevierStyleSup">94,95</span></a>. <span class="elsevierStyleItalic">The use of dynamic variables such as SVV and PPV, instead of static variables, is advised for predicting response to the administration of fluids in patients with severe hemorrhage subjected to controlled mechanical ventilation and with a normal cardiac rhythm who fail to respond to initial resuscitation therapy (1B).</span></p></span></span><span id="sec0175" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0195">Laboratory monitoring</span><span id="sec0180" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0200">What laboratory test parameters are most useful for the management of massive hemorrhage?</span><p id="par0455" class="elsevierStylePara elsevierViewall">Among the laboratory test parameters of greatest usefulness in assessing the evolution of patients with MH, mention must be made of the early and serial determination of basic hematological values such as hemoglobin, lactate, base excess (BE) and coagulation parameters (prothrombin time [PT], activated partial thromboplastin time [aPTT], fibrinogen<a class="elsevierStyleCrossRef" href="#fn0005"><span class="elsevierStyleSup">1</span></a> and platelets) for detecting the presence of coagulopathy is soon as possible–particularly in the presence of hypothermia and acidosis. These tests appear to yield altered results in early stages and are good prognostic indicators in these patients. The inclusion of arterial lactate, in addition to base excess, contributes to differentiate the most seriously ill patients.</p><p id="par0460" class="elsevierStylePara elsevierViewall">The adoption of so-called point of care devices (used to monitor blood parameters at the patient bedside) has greatly improved the availability and utilization of these tests in evaluating patients with MH. They have also shortened the time required for the sample to reach the place where it is processed, and the time required to obtain the results.</p><p id="par0465" class="elsevierStylePara elsevierViewall">Furthermore, the utilization of viscoelastic tests such as thromboelastography (TEG) and rotational thromboelastometry (ROTEM<span class="elsevierStyleSup">®</span>) can help detect, control and orientate the treatment of coagulopathy associated to acute hemorrhage, particularly in the presence of the lethal triad (hypothermia, acidosis and coagulopathy).</p><p id="par0470" class="elsevierStylePara elsevierViewall">Among the laboratory data used to monitor coagulopathy, mention must be made of the early and serial determination of aPTT, PT, the International Normalized Ratio (INR), fibrinogen (Fb) via the Clauss method, and platelets.<a class="elsevierStyleCrossRef" href="#bib1200"><span class="elsevierStyleSup">41</span></a> Likewise, in surgical or trauma patients with severe hemorrhage, completion of the coagulation study with TEG or ROTEM<span class="elsevierStyleSup">®</span> should be considered, conditioned to their availability in each center.<a class="elsevierStyleCrossRefs" href="#bib1475"><span class="elsevierStyleSup">96,97</span></a></p><p id="par0475" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 19</span></span><a class="elsevierStyleCrossRefs" href="#bib1200"><span class="elsevierStyleSup">41,43,44,98</span></a>. <span class="elsevierStyleItalic">The early and serial determination of hematological parameters such as hemoglobin, lactate, base excess (both arterial and venous) and coagulation tests (prothrombin time, INR, activated partial thromboplastin time [aPTT], fibrinogen and platelets) is advised in order to ensure the early detection of coagulopathy. These tests appear to yield altered results in early stages and are good prognostic indicators in these patients. (1C).</span></p><p id="par0480" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 20</span></span><a class="elsevierStyleCrossRefs" href="#bib1490"><span class="elsevierStyleSup">99,100</span></a>. <span class="elsevierStyleItalic">The use of viscoelastic tests such as ROTEM</span><span class="elsevierStyleSup"><span class="elsevierStyleItalic">®</span></span><span class="elsevierStyleItalic">or TEG is recommended, since they can help detect, control and orientate the treatment of coagulopathy associated to acute hemorrhage, particularly in the presence of the lethal triad (hypothermia, acidosis and coagulopathy) (1C).</span></p></span></span></span><span id="sec0185" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0205">Administration of blood components</span><span id="sec0190" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0210">Red cell concentrate</span><span id="sec0195" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0215">What are the criteria for the transfusion of red cell concentrates in a patient with massive hemorrhage?</span><p id="par0485" class="elsevierStylePara elsevierViewall">In general, terms, both the European and the Australian guides suggest the avoidance of red cell concentrate transfusions in the presence of hemoglobin values above 10<span class="elsevierStyleHsp" style=""></span>g/dl,<a class="elsevierStyleCrossRefs" href="#bib1295"><span class="elsevierStyleSup">60,93</span></a> though special consideration is indicated in the case of low-weight patients and elderly individuals.<a class="elsevierStyleCrossRef" href="#bib1500"><span class="elsevierStyleSup">101</span></a></p><p id="par0490" class="elsevierStylePara elsevierViewall">In certain scenarios such as heart surgery and patients with ischemic heart disease, hemoglobin levels of above 9<span class="elsevierStyleHsp" style=""></span>g/dl should be reached.<a class="elsevierStyleCrossRefs" href="#bib1505"><span class="elsevierStyleSup">102,103</span></a> However, in patients who are clinically stable, more restricted transfusion criteria apply, with hemoglobin levels of 8<span class="elsevierStyleHsp" style=""></span>g/dl.<a class="elsevierStyleCrossRef" href="#bib1515"><span class="elsevierStyleSup">104</span></a></p><p id="par0495" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 21</span></span><a class="elsevierStyleCrossRefs" href="#bib1025"><span class="elsevierStyleSup">6,93,101–104</span></a>. <span class="elsevierStyleItalic">Transfusion protocols in massive hemorrhage should function with an alarm system defined by the hemotherapy commission of each individual hospital, as a consensus-based interdisciplinary protocol, with period assessment of its efficacy and safety (2C).</span></p><p id="par0500" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 22</span></span><a class="elsevierStyleCrossRefs" href="#bib1025"><span class="elsevierStyleSup">6,93,105</span></a>. <span class="elsevierStyleItalic">In the context of massive hemorrhage, it is advisable to consider the early transfusion of red cell concentrates. As an orientation in this regard, the evolution of both clinical parameters (BP, HR, SI) and laboratory values (hemoglobin, lactate, base excess [BE]) should be taken into account, avoiding transfusions based on isolated determinations, and in all cases individualizing the clinical situation of the patient (1B).</span></p></span></span><span id="sec0200" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0220">Optimum treatment ratios</span><span id="sec0205" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0225">Is there an optimum ratio for the administration of blood components in the management of massive hemorrhage?</span><p id="par0505" class="elsevierStylePara elsevierViewall">There is great controversy regarding the optimum ratio for the administration of blood components in the management of massive hemorrhage. Initial studies suggested that a FP:RCC ratio of 1:1 reduces mortality in war injuries.<a class="elsevierStyleCrossRefs" href="#bib1525"><span class="elsevierStyleSup">106,107</span></a> Additional cohort studies appeared to indicate a beneficial effect of the 1:1 ratio in other massive bleeding scenarios. In 2010, however, a more detailed review of the United States Army in 777 trauma patients transfused with the 1:1 ratio was unable to demonstrate a decrease in mortality.<a class="elsevierStyleCrossRef" href="#bib1535"><span class="elsevierStyleSup">108</span></a> In contrast, different studies pointed to the possibility that 1:1 protocols might induce undesirable effects that outweigh the benefits.<a class="elsevierStyleCrossRefs" href="#bib1540"><span class="elsevierStyleSup">109–112</span></a> It was found that:<ul class="elsevierStyleList" id="lis0025"><li class="elsevierStyleListItem" id="lsti0095"><span class="elsevierStyleLabel">1)</span><p id="par0510" class="elsevierStylePara elsevierViewall">The use of fixed-ratio protocols caused patients who do not need plasma to receive it needlessly.</p></li><li class="elsevierStyleListItem" id="lsti0100"><span class="elsevierStyleLabel">2)</span><p id="par0515" class="elsevierStylePara elsevierViewall">The plasma in excess received by the patients generated problems of fluid overload, increased the risk of multiorgan failure, and raised the number of complications (respiratory distress, multiorgan failure and infections).</p></li></ul></p><p id="par0520" class="elsevierStylePara elsevierViewall">There is no evidence that transfusion strategies based on fixed-ratio protocols, with the administration of red cell concentrates/fresh plasma/platelet concentrates (RCC:FP:PC) in 1:1:1 proportion, offer a favorable risk-benefit relationship in MH. Furthermore, there is a high risk that the use of strategies of this kind in non-trauma patients may result in more undesirable effects than benefits.<a class="elsevierStyleCrossRef" href="#bib1560"><span class="elsevierStyleSup">113</span></a> In sum, although benefits have been suggested with the use of fixed-proportion (1:1:1 or 2:1:1) transfusion strategies, it has not been possible to demonstrate the superiority of one strategy over the rest. In some situations, the use of fixed-ratio protocols can cause complications. A more detailed study is required of the benefit-risk profile of the 1:1:1 transfusion protocol in patients with severe trauma.</p><p id="par0525" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 23</span></span><a class="elsevierStyleCrossRefs" href="#bib1025"><span class="elsevierStyleSup">6,41,93</span></a>. <span class="elsevierStyleItalic">It is advisable to manage MH with a high proportion of fresh plasma and platelets in relation to the red cell concentrates, since improved results appear to be obtained, particularly in polytraumatized patients (improvements in survival and in the prevention and control of coagulopathy) (2C).</span></p></span></span><span id="sec0210" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0230">Fresh plasma</span><span id="sec0215" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0235">How and when should fresh plasma be used?</span><p id="par0530" class="elsevierStylePara elsevierViewall">The transfusion of FP remains the standard for preventing and treating coagulopathy in MH, though its inconveniences include the risk of transfusion-associated circulatory overload (TACO) (more frequent in the presence of heart failure), transfusion-related acute lung injury (TRALI), or the need in some cases to wait for as long as 45<span class="elsevierStyleHsp" style=""></span>min for transfusion to become available.<a class="elsevierStyleCrossRef" href="#bib1565"><span class="elsevierStyleSup">114</span></a></p><p id="par0535" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 24</span></span><a class="elsevierStyleCrossRefs" href="#bib1570"><span class="elsevierStyleSup">115–118</span></a>. <span class="elsevierStyleItalic">In the context of massive hemorrhage, it is advisable to start the administration of fresh plasma early in order to prevent and/or treat coagulopathy. The recommended volume of fresh plasma depends on clinical (control of bleeding) and/or laboratory test parameters (thromboelastographic and/or standard coagulation values) (1C).</span></p></span></span><span id="sec0220" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0240">Platelets</span><span id="sec0225" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0245">What is the limiting circulating platelet count for starting the transfusion of platelet concentrates?</span><p id="par0540" class="elsevierStylePara elsevierViewall">There is no solid scientific evidence regarding the platelet count capable of guaranteeing hemostasis. In general, use is made of the opinions and/or conclusions of previous studies.<a class="elsevierStyleCrossRef" href="#bib1200"><span class="elsevierStyleSup">41</span></a> The base concept is that in normal situations the transfusion of platelets is not necessary in patients with counts of over 100<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">9</span>/l. The optimum count for restoring hemostasis in actively bleeding patients is not known.</p><p id="par0545" class="elsevierStylePara elsevierViewall">There is some agreement that the platelet counts should be kept above 50<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">9</span>/l in patients with active bleeding.<a class="elsevierStyleCrossRefs" href="#bib1590"><span class="elsevierStyleSup">119,120</span></a> Some experts advocate a higher platelet count (75<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">9</span>/l) in patients with active bleeding or in which bleeding persists with counts of 50<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">9</span>/l.<a class="elsevierStyleCrossRefs" href="#bib1600"><span class="elsevierStyleSup">121,122</span></a> Counts above 100<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">9</span>/l would be more adequate for polytraumatized patients with brain injuries and massive bleeding.</p><p id="par0550" class="elsevierStylePara elsevierViewall">No platelet count limits have been specifically defined for massive gynecological hemorrhage, liver transplantation or cardiovascular surgery, and when disseminated intravascular coagulation (DIC) with or without hyperfibrinolysis is moreover present, the indication of platelet administration must be based on the severity of bleeding and the specific conditions that may have given rise to MH. Therefore, given the platelet dysfunctions associated to these clinical situations, the limiting platelet count should not be used as reference.</p><p id="par0555" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 25</span></span><a class="elsevierStyleCrossRefs" href="#bib1200"><span class="elsevierStyleSup">41,119–122</span></a>. <span class="elsevierStyleItalic">The administration of platelet concentrates (PC) is recommended for maintaining a platelet count above 50</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">×</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">10</span><span class="elsevierStyleSup"><span class="elsevierStyleItalic">9</span></span><span class="elsevierStyleItalic">/l in trauma patients (1C).</span></p><p id="par0560" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 26</span></span><a class="elsevierStyleCrossRefs" href="#bib1200"><span class="elsevierStyleSup">41,121–123</span></a>. <span class="elsevierStyleItalic">Platelet transfusions are recommended for maintaining counts above 75</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">×</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">10</span><span class="elsevierStyleSup"><span class="elsevierStyleItalic">9</span></span><span class="elsevierStyleItalic">/l in patients with active bleeding when hemorrhage does not cease in the presence of counts of 50</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">×</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">10</span><span class="elsevierStyleSup"><span class="elsevierStyleItalic">9</span></span><span class="elsevierStyleItalic">/l (2C).</span></p><p id="par0565" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 27</span></span><a class="elsevierStyleCrossRefs" href="#bib1200"><span class="elsevierStyleSup">41,119,121,124</span></a>. <span class="elsevierStyleItalic">The maintenance of platelet counts above 100</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">×</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">10</span><span class="elsevierStyleSup"><span class="elsevierStyleItalic">9</span></span><span class="elsevierStyleItalic">/l is advised in patients with massive bleeding and traumatic brain injury (2C).</span></p></span><span id="sec0230" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0250">What platelet dose should be administered, and with what frequency?</span><p id="par0570" class="elsevierStylePara elsevierViewall">There is no solid scientific evidence in this regard. The opinions come from publications of the Working Group created in 2005, and which has published guides in 2007, 2010 and 2013. Hospitals can receive platelets in the form of PC fractionated from whole blood units, pools obtained from mixing 4–5 concentrates (one pool being equivalent to 4–5 concentrates), or units obtained through single donor apheresis. There are no recommendations regarding the frequency of administration.</p><p id="par0575" class="elsevierStylePara elsevierViewall">The increases in platelet counts are greater in the case of platelet transfusions obtained through identical ABO group apheresis, and also in the case of platelets stored for three days compared with 4–5 days.<a class="elsevierStyleCrossRef" href="#bib1620"><span class="elsevierStyleSup">125</span></a> The origin (apheresis versus pool), ABO compatibility, and the duration of storage have a moderate effect upon the absolute and corrected post-transfusion platelet count increments, but have no measurable impact upon the prevention of the hemorrhage.<a class="elsevierStyleCrossRefs" href="#bib1620"><span class="elsevierStyleSup">125–128</span></a> In thrombocytopenic patients, PC not subjected to biological inactivation produce greater post-transfusion platelet count increments, but there is no evidence suggesting greater hemostatic efficacy in such cases.<a class="elsevierStyleCrossRef" href="#bib1640"><span class="elsevierStyleSup">129</span></a> No studies have been made in patients with massive hemorrhage.</p><p id="par0580" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 28</span></span><a class="elsevierStyleCrossRefs" href="#bib1200"><span class="elsevierStyleSup">41,100,119,122,126,130</span></a>. <span class="elsevierStyleItalic">An initial dose of 4–8 PC (equivalent to 1–2 pools) is recommended. The administration frequency should be adjusted according to the persistence of hemorrhage, the counts reached with the starting dose, and the patient response to other measures adopted to control the bleeding (2C).</span></p></span><span id="sec0235" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0255">What is the order of administration of platelet concentrates with respect to other blood products (plasma, red cell concentrates or other hemostatic agents)?</span><p id="par0585" class="elsevierStylePara elsevierViewall">An increase in hematocrit to 30% reduces the risk of hemorrhage in patients with thrombocytopenia. Liumbruno et al.<a class="elsevierStyleCrossRef" href="#bib1605"><span class="elsevierStyleSup">122</span></a> recommend trying to raise hematocrit to close to 30% in order to reduce the risk of hemorrhage (recommendation 1C+). Increasing the hematocrit to 30% improves platelet hemostatic efficacy.<a class="elsevierStyleCrossRefs" href="#bib1650"><span class="elsevierStyleSup">131–134</span></a> In patients with MH, it seems to be advisable to transfuse PC after having administered red cell concentrates and FP.<a class="elsevierStyleCrossRef" href="#bib1650"><span class="elsevierStyleSup">131</span></a></p></span><span id="sec0240" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0260">What are the side effects of the administration of platelets? What safety aspects should be taken into account to avoid them?</span><p id="par0590" class="elsevierStylePara elsevierViewall">The transfusion of platelets can produce adverse reactions of variable severity. One out of every 50,000 platelet units may be contaminated and cause complications secondary to severe sepsis. The storage and form of production of the platelets (pool, buffy coat or apheresis) can modify the biological response to the transfused concentrates and either reduce (apheresis) or increase (pool) patient exposure to one or more donors. The biological risk increases in patients subjected to massive transfusion, and the associated severity can increase depending on the biocomponent ratios used.<a class="elsevierStyleCrossRef" href="#bib1670"><span class="elsevierStyleSup">135</span></a> Although there is no evidence of any clinical benefit from the use of different concentrates, storage times or treatments for reducing the presence of pathogens, the administration of concentrates stored for shorter periods of time, and the use of apheresis units, appears to reduce the biological risks.</p><p id="par0595" class="elsevierStylePara elsevierViewall">The transfusion of FP and PC can cause transfusion-related acute lung injury (TRALI), which is infrequent and may go unnoticed, but is associated to high mortality rates. It is more common after the administration of FP, but has also been related to PC, which are vehiculized with plasma.<a class="elsevierStyleCrossRef" href="#bib1675"><span class="elsevierStyleSup">136</span></a> The utilization of plasma from male blood donations, the use of lesser plasma volumes in the concentrates, and the utilization of single donors versus pools all contribute to reduce the risk of these complications.</p></span></span><span id="sec0245" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0265">Other blood components</span><span id="sec0250" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0270">Is the use of albumin justified in patients with massive hemorrhage?</span><p id="par0600" class="elsevierStylePara elsevierViewall">The administration of albumin remains a controversial issue in the management of MH, since there are no conclusive studies supporting this practice. Albumin has not been found to be superior in volume replacement when compared with artificial colloids and crystalloids.<a class="elsevierStyleCrossRefs" href="#bib1680"><span class="elsevierStyleSup">137,138</span></a></p><p id="par0605" class="elsevierStylePara elsevierViewall">Albumin formulations are available at concentrations of 5% and 20%. The lesser concentration solution (5%) is the only formulation indicated for volume replacement. The 20% concentration is exclusively administered for the treatment of severe hypoproteinemia requiring replacement therapy.<a class="elsevierStyleCrossRef" href="#bib1690"><span class="elsevierStyleSup">139</span></a></p><p id="par0610" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 29</span></span><a class="elsevierStyleCrossRefs" href="#bib1680"><span class="elsevierStyleSup">137–139</span></a>. <span class="elsevierStyleItalic">The systematic use of albumin in patients with massive hemorrhage is not advised (1C).</span></p></span><span id="sec0255" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0275">What is the role of topical hemostatic agents in the control of hemorrhage?</span><p id="par0615" class="elsevierStylePara elsevierViewall">The ideal topical hemostatic agent is that which affords rapid local bleeding control without affecting the systemic coagulation mechanisms. Furthermore, it should not be able to cross the filtering systems, and should not be of human or bovine origin, in order to avoid the transmission of infections. These characteristics can be offered by recombinant agents that contain chitosan, thereby obviating the risk of transmission of viral diseases.<a class="elsevierStyleCrossRefs" href="#bib1695"><span class="elsevierStyleSup">140,141</span></a> Topical agents have been successfully used in different surgical procedures, including heart, urological, gynecological and gastrointestinal surgery, and trauma surgery.</p><p id="par0620" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 30</span></span><a class="elsevierStyleCrossRefs" href="#bib1200"><span class="elsevierStyleSup">41,140,141</span></a>. <span class="elsevierStyleItalic">The use of topical hemostatic agents is recommended in combination with conventional measures in bleeding associated to different surgical procedures (1B).</span></p></span></span></span><span id="sec0260" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0280">Administration of hemostatic agents</span><span id="sec0265" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0285">Prothrombin complex</span><span id="sec0270" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0290">What are the indications of prothrombin complex concentrate in the context of MH?</span><p id="par0625" class="elsevierStylePara elsevierViewall">In relation to the administration of prothrombin complex concentrate (PCC), the panel of experts recommends that both the indication and the dose and frequency of administration of PCC should be based on the specifications of the Summary of Product Characteristics.</p><p id="par0630" class="elsevierStylePara elsevierViewall">In the case of patients anticoagulated with anti-vitamin K drugs (warfarin or acenocoumarol) in the context of MH, we can use PCC as an effective alternative to plasma for the urgent reversal of the anticoagulant effect.<a class="elsevierStyleCrossRef" href="#bib1705"><span class="elsevierStyleSup">142</span></a> The starting dose of PCC (preferably comprising 4 factors, which is the formulation available in our setting) should be 50<span class="elsevierStyleHsp" style=""></span>IU/kg,<a class="elsevierStyleCrossRef" href="#bib1710"><span class="elsevierStyleSup">143</span></a> associated to a vitamin K dose of 10<span class="elsevierStyleHsp" style=""></span>mg i.v. Since the thrombogenic side effects of PCC have been associated to high doses and successive dose administrations, it is advisable to evaluate the INR value before a new PCC dose is administered: if the INR<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>1.5, another dose of PCC is not advised–though the clinical parameters also must be taken into account.<a class="elsevierStyleCrossRef" href="#bib1715"><span class="elsevierStyleSup">144</span></a></p><p id="par0635" class="elsevierStylePara elsevierViewall">In patients with MH not associated to the use of anti-vitamin K anticoagulants, the use of PCC as first line treatment is generally not recommended.<a class="elsevierStyleCrossRefs" href="#bib1710"><span class="elsevierStyleSup">143,144</span></a> Prothrombin complex concentrate can be used in selected cases, fundamentally in situations where FP is not timely available, if the patient is at risk of suffering transfusion-associated circulatory overload (TACO), or in the presence of a risk of TRALI.</p><p id="par0640" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 31</span></span><a class="elsevierStyleCrossRef" href="#bib1460"><span class="elsevierStyleSup">93</span></a>. <span class="elsevierStyleItalic">In the context of massive hemorrhage, the use of prothrombin complex concentrate is recommended in patients receiving treatment with anti-vitamin K anticoagulants for the rapid reversal of their effects (1C).</span></p><p id="par0645" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 32</span></span><a class="elsevierStyleCrossRef" href="#bib1460"><span class="elsevierStyleSup">93</span></a>. <span class="elsevierStyleItalic">In the context of massive hemorrhage, in patients not receiving treatment with oral anti-vitamin K anticoagulants, the use of prothrombin complex concentrate as first option for the correction of coagulopathy is not recommended. It may be used in selected patients, depending on the urgency of treatment and the availability of FP (1C).</span></p><p id="par0650" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 33</span></span><a class="elsevierStyleCrossRef" href="#bib1520"><span class="elsevierStyleSup">105</span></a>. <span class="elsevierStyleItalic">It is advisable to regularly determine plasma fibrinogen using a coagulometric (Clauss) or viscoelastometric method (Fibtem with ROTEM</span><span class="elsevierStyleSup"><span class="elsevierStyleItalic">®</span></span><span class="elsevierStyleItalic">or Functional Fibrinogen with TEG), in order to ensure the effectiveness of the prothrombin complex concentrate, since a fibrinogen level of <2</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">g/l in this clinical situation does not guarantee good hemostasis (1C)</span>.</p><p id="par0655" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 34</span></span><a class="elsevierStyleCrossRef" href="#bib1710"><span class="elsevierStyleSup">143</span></a>. <span class="elsevierStyleItalic">It is advisable to administer intravenous vitamin K (10</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mg) in patients with massive hemorrhage treated with anti-vitamin K anticoagulants (1C). However, it should not be administered in a similar context in those patients anticoagulated with a direct action oral anticoagulant (1C).</span></p></span><span id="sec0275" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0295">Is the use of activated prothrombin complex recommended in the context of massive hemorrhage?</span><p id="par0660" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 35</span></span><a class="elsevierStyleCrossRefs" href="#bib1720"><span class="elsevierStyleSup">145,146</span></a>. <span class="elsevierStyleItalic">It is not advisable to use activated prothrombin complex in massive hemorrhage, since such treatment is specifically indicated in congenital hemophilia with inhibitor and acquired hemophilia (1C).</span></p></span><span id="sec0280" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0300">What are the required safety precautions when using prothrombin complex?</span><p id="par0665" class="elsevierStylePara elsevierViewall">Prothrombin complex concentrate is generally safe, though some complications (fundamentally of a thrombotic nature) have been documented in certain scenarios.<a class="elsevierStyleCrossRef" href="#bib1730"><span class="elsevierStyleSup">147</span></a></p><p id="par0670" class="elsevierStylePara elsevierViewall">It is advisable to use PCC with caution in patients with thrombotic or cardiovascular risk factors, in individuals with artificial heart valves, with a history of ischemic stroke, or in patients subjected to revascularization after acute coronary syndrome, taking care not to exceed a dose of 20–25<span class="elsevierStyleHsp" style=""></span>IU/kg. Likewise, PCC should be used with caution in polytraumatized patients, due to the risk of suffering thromboembolic events.<a class="elsevierStyleCrossRefs" href="#bib1710"><span class="elsevierStyleSup">143,147–149</span></a></p><p id="par0675" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 36</span></span><a class="elsevierStyleCrossRefs" href="#bib1730"><span class="elsevierStyleSup">147,148</span></a>. <span class="elsevierStyleItalic">Caution is recommended when using prothrombin complexes in patients with life-threatening massive hemorrhage or who must undergo surgery without delay and are at a high risk of suffering thrombosis. A maximum dose of 20–25</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">IU/kg is advised (2C).</span></p></span></span><span id="sec0285" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0305">Fibrinogen</span><span id="sec0290" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0310">Determination of fibrinogen</span><p id="par0680" class="elsevierStylePara elsevierViewall">Fibrinogen (Fb) is the factor exhibiting the earliest decrease in concentration after severe hemorrhage.<a class="elsevierStyleCrossRefs" href="#bib1745"><span class="elsevierStyleSup">150,151</span></a> The earliness and intensity of this decrease in concentration is predictive of the severity of hemorrhage.<a class="elsevierStyleCrossRef" href="#bib1755"><span class="elsevierStyleSup">152</span></a></p><p id="par0685" class="elsevierStylePara elsevierViewall">A number of techniques are available for the determination of Fb concentration, and their incorrect application or interpretation can complicate the diagnosis and decisions regarding the transfusion strategy to be used. The determinations of Fb derived from prothrombin time using automated coagulometers are not reliable for the management of MH. The Clauss technique is recommended for diagnostic purposes, or when decisions referred to the clinical management of patients with MH must be made.<a class="elsevierStyleCrossRef" href="#bib1760"><span class="elsevierStyleSup">153</span></a> The determination of FIBTEM with ROTEM<span class="elsevierStyleSup">®</span> or Functional Fibrinogen in TEG allows us to quickly detect alterations in the Fb levels in trauma patients. In this regard, it has been confirmed that the determination of Fb using the FIBTEM test in ROTEM<span class="elsevierStyleSup">®</span> is closely correlated to the values obtained with the Clauss method.<a class="elsevierStyleCrossRefs" href="#bib1765"><span class="elsevierStyleSup">154,155</span></a> The Fb values may be erroneous in samples from hemodiluted patients, and particularly in those who have received colloids. The determination of Fb via FIBTEM in ROTEM<span class="elsevierStyleSup">®</span> or of Functional Fibrinogen in TEG is a useful option and is faster than the determination of Fb using the Clauss method.</p><p id="par0690" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 37</span></span><a class="elsevierStyleCrossRefs" href="#bib1490"><span class="elsevierStyleSup">99,153–155</span></a>. <span class="elsevierStyleItalic">The determination of fibrinogen using the Clauss method or FIBTEM in ROTEM</span><span class="elsevierStyleSup"><span class="elsevierStyleItalic">®</span></span><span class="elsevierStyleItalic">or Functional Fibrinogen in TEG is recommended for diagnostic purposes, or when decisions referred to the clinical management of patients with massive hemorrhage must be made (1C).</span></p></span><span id="sec0295" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0315">What is the plasma fibrinogen threshold for the administration of fibrinogen?</span><p id="par0695" class="elsevierStylePara elsevierViewall">Fibrinogen is the main coagulation substrate and the most abundant factor in plasma. However, it is also the factor that decreases fastest to critical levels in the case of MH.<a class="elsevierStyleCrossRef" href="#bib1745"><span class="elsevierStyleSup">150</span></a></p><p id="par0700" class="elsevierStylePara elsevierViewall">The bleeding tendency increases when the Fb concentration drops to below 1.5–2.0<span class="elsevierStyleHsp" style=""></span>g/l.<a class="elsevierStyleCrossRefs" href="#bib1755"><span class="elsevierStyleSup">152,156,157</span></a> Recent European guides recommend the administration of Fb when the abovementioned threshold is not reached,<a class="elsevierStyleCrossRefs" href="#bib1200"><span class="elsevierStyleSup">41,93</span></a> considering that clot firmness increases linearly with the concentration of Fb, and that a minimum threshold of 2<span class="elsevierStyleHsp" style=""></span>g/l is needed to reach optimum clot formation.<a class="elsevierStyleCrossRef" href="#bib1785"><span class="elsevierStyleSup">158</span></a> However, further studies are needed to consolidate the evidence supporting this recommendation.<a class="elsevierStyleCrossRef" href="#bib1790"><span class="elsevierStyleSup">159</span></a></p><p id="par0705" class="elsevierStylePara elsevierViewall">On the other hand, rapid coagulation testing is essential for the early treatment of MH. An excellent correlation has been observed between the concentration of Fb and all the ROTEM<span class="elsevierStyleSup">®</span> parameters, particularly FIBTEM.<a class="elsevierStyleCrossRef" href="#bib1795"><span class="elsevierStyleSup">160</span></a> In effect, in both pediatric surgery and in polytraumatized patients,<a class="elsevierStyleCrossRefs" href="#bib1770"><span class="elsevierStyleSup">155,161</span></a> a maximum clot firmness (MCF) in FIBTEM of between 7 and 10<span class="elsevierStyleHsp" style=""></span>mm is associated to plasma Fb levels of 1.5–2<span class="elsevierStyleHsp" style=""></span>g/l. It is considered that FIBTEM-MCF <7<span class="elsevierStyleHsp" style=""></span>mm indicates alteration of fibrin polymerization and a decrease in Fb concentration to under 1.5–1.8<span class="elsevierStyleHsp" style=""></span>g/l.<a class="elsevierStyleCrossRefs" href="#bib1130"><span class="elsevierStyleSup">27,155,162,163</span></a> Calculation of the Fb levels via TEG indicates a normal range of Functional Fibrinogen Level (FLEV) values of between 2 and 4.45<span class="elsevierStyleHsp" style=""></span>g/l, with a good correlation to the Clauss method.<a class="elsevierStyleCrossRef" href="#bib1815"><span class="elsevierStyleSup">164</span></a></p><p id="par0710" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 38</span></span><a class="elsevierStyleCrossRefs" href="#bib1200"><span class="elsevierStyleSup">41,93,150,152,155–158,160,161,163,165–167</span></a>. <span class="elsevierStyleItalic">Since adequate clot firmness only appears to be achieved from a plasma Fb concentration of over 2</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">g/l, it is advisable to administer Fb when this threshold is not reached as determined by the Clauss method, FIBTEM-MCF in ROTEM</span><span class="elsevierStyleSup"><span class="elsevierStyleItalic">®</span></span><span class="elsevierStyleItalic">is under 7</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mm or, by equivalence, the maximum FLEV amplitude is under 10</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mm (1C).</span></p></span><span id="sec0300" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0320">What is the fibrinogen starting dose?</span><p id="par0715" class="elsevierStylePara elsevierViewall">The Fb concentrate dose should be individualized according to the severity of bleeding and the current plasma Fb concentration. The dose is calculated based on the following formula<a class="elsevierStyleCrossRef" href="#bib1835"><span class="elsevierStyleSup">168</span></a>:</p><p id="par0720" class="elsevierStylePara elsevierViewall">Fb dose (g)<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>desired Fb increment (g/l)<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>plasma volume (l)</p><p id="par0725" class="elsevierStylePara elsevierViewall">If we assume a plasma volume of 0.04<span class="elsevierStyleHsp" style=""></span>l/kg, this formula shows that for each g of Fb administered, the plasma Fb level increases an average of 0.25–0.28<span class="elsevierStyleHsp" style=""></span>g/l.<a class="elsevierStyleCrossRef" href="#bib1840"><span class="elsevierStyleSup">169</span></a></p><p id="par0730" class="elsevierStylePara elsevierViewall">However, when Fb replacement is guided by rotational thromboelastometry, the dose is calculated as follows:<a class="elsevierStyleCrossRef" href="#bib1845"><span class="elsevierStyleSup">170</span></a></p><p id="par0735" class="elsevierStylePara elsevierViewall">Fb dose (g)<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>FIBTEM-MCF (mm) target<span class="elsevierStyleHsp" style=""></span>−<span class="elsevierStyleHsp" style=""></span>actual FIBTEM-MCF (mm)<span class="elsevierStyleHsp" style=""></span>× <span class="elsevierStyleHsp" style=""></span>weight (kg)/140</p><p id="par0740" class="elsevierStylePara elsevierViewall">On an approximate basis, according to this formula, for each g of Fb administered, FIBTEM-MCF increases 2<span class="elsevierStyleHsp" style=""></span>mm.<a class="elsevierStyleCrossRef" href="#bib1850"><span class="elsevierStyleSup">171</span></a> A similar calculation can be made for TEG based on the correlation of FLEV to the values of the Clauss method.<a class="elsevierStyleCrossRef" href="#bib1815"><span class="elsevierStyleSup">164</span></a></p><p id="par0745" class="elsevierStylePara elsevierViewall">Different studies have been published on the correction of coagulopathy or reduction of the transfusion requirements and the administration of Fb. As an example, in trauma patients, non-randomized studies have shown the administration of Fb to be effective in securing the mentioned objectives.<a class="elsevierStyleCrossRefs" href="#bib1490"><span class="elsevierStyleSup">99,172,173</span></a> Likewise, in orthopedic surgery, the administration of Fb appears to revert dilutional coagulopathy.<a class="elsevierStyleCrossRef" href="#bib1865"><span class="elsevierStyleSup">174</span></a> In a randomized study of surgical patients subjected to radical cystectomy, the administration of Fb was found to reduce the transfusion needs.<a class="elsevierStyleCrossRef" href="#bib1820"><span class="elsevierStyleSup">165</span></a> More studies have been published in recent years in relation to cardiovascular surgery, involving both randomized<a class="elsevierStyleCrossRef" href="#bib1870"><span class="elsevierStyleSup">175</span></a> and non-randomized designs,<a class="elsevierStyleCrossRefs" href="#bib1845"><span class="elsevierStyleSup">170,175–179</span></a> and demonstrating that the administration of Fb reduces the transfusion needs. Many of these authors have used a model to individualize the Fb dose.<a class="elsevierStyleCrossRef" href="#bib1870"><span class="elsevierStyleSup">175</span></a> Thus, when bleeding in 5<span class="elsevierStyleHsp" style=""></span>min totals 60–250<span class="elsevierStyleHsp" style=""></span>g, they administered a Fb dose calculated to reach a FIBTEM-MCF of approximately 22<span class="elsevierStyleHsp" style=""></span>mm, equivalent to a plasma level of 3.6<span class="elsevierStyleHsp" style=""></span>g/l, which would optimize the interaction between Fb and the available thrombin after cardiopulmonary bypass, and would improve hemostasis.<a class="elsevierStyleCrossRef" href="#bib1875"><span class="elsevierStyleSup">176</span></a></p><p id="par0750" class="elsevierStylePara elsevierViewall">Regarding the prophylactic use of Fb, a randomized coronary surgery study has been published in which the authors administered 2<span class="elsevierStyleHsp" style=""></span>g of Fb to patients with a preoperative plasma level of under 3.8<span class="elsevierStyleHsp" style=""></span>g/l, with confirmation of a decrease in postoperative bleeding.<a class="elsevierStyleCrossRef" href="#bib1895"><span class="elsevierStyleSup">180</span></a> In contrast, another randomized multicenter study has not confirmed the efficacy of the preventive administration of 2<span class="elsevierStyleHsp" style=""></span>g of Fb in postpartum hemorrhage among patients with normal blood fibrinogen levels.<a class="elsevierStyleCrossRef" href="#bib1900"><span class="elsevierStyleSup">181</span></a></p><p id="par0755" class="elsevierStylePara elsevierViewall">There are also two systematic reviews and a Cochrane review which have concluded that treatment with Fb reduces the transfusion needs and postoperative bleeding.<a class="elsevierStyleCrossRefs" href="#bib1790"><span class="elsevierStyleSup">159,182,183</span></a> However, in surgical patients it has been seen that the plasma Fb increments are short-lasting, and that 24<span class="elsevierStyleHsp" style=""></span>h after surgery the Fb levels are similar to those recorded in the patients who received no such treatment.<a class="elsevierStyleCrossRefs" href="#bib1820"><span class="elsevierStyleSup">165,180,184</span></a></p><p id="par0760" class="elsevierStylePara elsevierViewall">Controlled studies are still needed to investigate the possibility of thromboembolic events related to the administration of Fb.</p><p id="par0765" class="elsevierStylePara elsevierViewall">In sum, more controlled studies are needed to evidence the efficacy of Fb and its use in the different clinical scenarioss.<a class="elsevierStyleCrossRef" href="#bib1790"><span class="elsevierStyleSup">159</span></a> Likewise, it should be underscored that cryoprecipitates are no longer used as a source of Fb in many European countries, due to their adverse effects and difficult dosing characteristics, and have been replaced by Fb concentrates.<a class="elsevierStyleCrossRefs" href="#bib1920"><span class="elsevierStyleSup">185–189</span></a></p><p id="par0770" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 39</span></span><a class="elsevierStyleCrossRefs" href="#bib1200"><span class="elsevierStyleSup">41,93,165</span></a>. <span class="elsevierStyleItalic">A starting dose of 25–50<span class="elsevierStyleHsp" style=""></span>mg/kg of fibrinogen concentrate is recommended when the advised plasma fibrinogen threshold is not reached (2C).</span></p></span></span><span id="sec0305" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0325">Factor VIIa</span><span id="sec0310" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0330">What are the indications for the administration of factor VIIa in the context of massive hemorrhage?</span><p id="par0775" class="elsevierStylePara elsevierViewall">The approved indications of factor VIIa are the prevention and treatment of hemorrhage in patients with congenital hemophilia A or B, congenital factor VII deficiency, acquired hemophilia and Glanzmann's thrombasthenia at a dose of 90<span class="elsevierStyleHsp" style=""></span>μg/kg every 2<span class="elsevierStyleHsp" style=""></span>h until the bleeding episode ceases.<a class="elsevierStyleCrossRefs" href="#bib1945"><span class="elsevierStyleSup">190–192</span></a></p><p id="par0780" class="elsevierStylePara elsevierViewall">Regarding use outside its established indications, ex vivo studies and investigations in healthy volunteers have shown that factor rVIIa is able to antagonize the effect of many anticoagulants,<a class="elsevierStyleCrossRefs" href="#bib1960"><span class="elsevierStyleSup">193–195</span></a> including the new oral anticoagulants and vitamin K antagonists.<a class="elsevierStyleCrossRefs" href="#bib1975"><span class="elsevierStyleSup">196–198</span></a> However, its use is not advised for the routine reversal of coumarin-induced coagulopathy,<a class="elsevierStyleCrossRefs" href="#bib1990"><span class="elsevierStyleSup">199,200</span></a> since it is unable to reduce mortality when used for this purpose.<a class="elsevierStyleCrossRef" href="#bib2000"><span class="elsevierStyleSup">201</span></a> In view of the lack of clinical evidence in favor of its effectiveness, and since some studies have reported an increase in thrombosis in patients administered factor rVIIa, its administration should only be considered as a last option in patients with bleeding complications who are receiving treatment with anticoagulants that lack a specific antidote or in which bleeding proves incoercible despite application of all the necessary measures.<a class="elsevierStyleCrossRefs" href="#bib1960"><span class="elsevierStyleSup">193,202–204</span></a> A single dose of 90<span class="elsevierStyleHsp" style=""></span>μg/kg is recommended.<a class="elsevierStyleCrossRefs" href="#bib2020"><span class="elsevierStyleSup">205,206</span></a></p><p id="par0785" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 40</span></span><a class="elsevierStyleCrossRefs" href="#bib1945"><span class="elsevierStyleSup">190–206</span></a>. <span class="elsevierStyleItalic">Factor VIIa is not recommended as a routine first level option in the treatment of massive hemorrhage (1B).</span></p></span></span><span id="sec0315" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0335">Antifibrinolytic agents</span><span id="sec0320" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0340">In what context are antifibrinolytic agents used in massive hemorrhage?</span><p id="par0790" class="elsevierStylePara elsevierViewall">Hyperfibrinolysis is a basic component in different medical and surgical scenarios involving MH. This would justify the use of antifibrinolytic agents such as tranexamic acid (TXA) or ¿-aminocaproic acid (EACA). However, TXA has shown superiority over EACA in controlling bleeding, and there is little scientific evidence supporting the use of the latter drug.<a class="elsevierStyleCrossRefs" href="#bib2030"><span class="elsevierStyleSup">207,208</span></a> The results of the CRASH-2 study show the early administration of TXA to be indicated in patients with hemorrhage associated to trauma.<a class="elsevierStyleCrossRef" href="#bib2040"><span class="elsevierStyleSup">209</span></a></p><p id="par0795" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 41</span></span><a class="elsevierStyleCrossRefs" href="#bib1200"><span class="elsevierStyleSup">41,93,209,210</span></a>. <span class="elsevierStyleItalic">The early administration (in the first 3<span class="elsevierStyleHsp" style=""></span>h) of tranexamic acid is advised in patients with massive hemorrhage secondary to trauma. The recommended starting dose is 1</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">g in 10</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">min, followed by an intravenous infusion of 1</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">g in 8</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">h. Later administration (over 3</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">h after trauma) is not advised, due to the increase in mortality associated to bleeding (1A).</span></p></span></span><span id="sec0325" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0345">Application of other measures and special situations</span><span id="sec0330" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0350">Angioembolization and endovascular procedures</span><p id="par0800" class="elsevierStylePara elsevierViewall">Angioembolization is an established process in the management of both acute and recurrent bleeding. Depending on the clinical indication, embolization may be selective or alternatively complete occlusion of a given vascular territory may be required. The technique is particularly useful in the management of gastrointestinal bleeding, hemoptysis, post-trauma hemorrhage or tumor bleeding.<a class="elsevierStyleCrossRef" href="#bib2050"><span class="elsevierStyleSup">211</span></a> There are no recommendations based on clinical guides, and individual assessment of each case is advised.<a class="elsevierStyleCrossRefs" href="#bib2055"><span class="elsevierStyleSup">212–214</span></a> The usefulness of endovascular devices for the treatment of bleeding depends on the clinical situation of the patient, the type of hemorrhage (acute or refractory) and its location.</p><p id="par0805" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 42</span></span><a class="elsevierStyleCrossRef" href="#bib2050"><span class="elsevierStyleSup">211</span></a>. <span class="elsevierStyleItalic">The evaluation of measures without transfusion, such as angioembolization or the use of endovascular procedures, is recommended for the treatment of massive hemorrhage in selected patients, provided such measures are available (1B).</span></p></span><span id="sec0335" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0355">Other prohemostatic drugs</span><p id="par0810" class="elsevierStylePara elsevierViewall">Regarding other therapeutic options, there is no evidence allowing recommendation of the use of factor XIII, antithrombin concentrates or protein C in patients with MH. Desmopressin (DDAVP) has been shown to be effective in the treatment and prevention of bleeding in patients with congenital or acquired primary hemostatic defects.<a class="elsevierStyleCrossRef" href="#bib2070"><span class="elsevierStyleSup">215</span></a> Different guides on the management of severe or massive hemorrhage recommend the administration of DDAVP in patients with Von Willebrand disease, in subjects with platelet dysfunction or in patients receiving treatment with acetylsalicylic acid (aspirin).<a class="elsevierStyleCrossRefs" href="#bib1200"><span class="elsevierStyleSup">41,93</span></a></p><p id="par0815" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 43</span></span><a class="elsevierStyleCrossRefs" href="#bib1200"><span class="elsevierStyleSup">41,93,216</span></a>. <span class="elsevierStyleItalic">Evaluation of the administration of desmopressin (0.3</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">μg/kg) is advised in bleeding patients Von Willebrand disease (1C).</span></p><p id="par0820" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 44</span></span><a class="elsevierStyleCrossRefs" href="#bib1200"><span class="elsevierStyleSup">41,93,216</span></a>. <span class="elsevierStyleItalic">Evaluation of the administration of desmopressin (0.3</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">μg/kg) is advised in uremic bleeding patients or those taking aspirin (2C).</span></p></span><span id="sec0340" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0360">Administration of calcium</span><p id="par0825" class="elsevierStylePara elsevierViewall">Calcium is essential for formation and stabilization of the blood clot and for correct platelet activation. Furthermore, calcium is required for cardiac contractility and the maintenance of systemic vascular resistance.</p><p id="par0830" class="elsevierStylePara elsevierViewall">In the context of bleeding patients, low plasma calcium levels at hospital admission may be related to the need for MT.<a class="elsevierStyleCrossRefs" href="#bib2080"><span class="elsevierStyleSup">217,218</span></a></p><p id="par0835" class="elsevierStylePara elsevierViewall">Likewise, hypocalcemia in the first 24<span class="elsevierStyleHsp" style=""></span>h may be related to both increased mortality and a greater need for polytransfusion measures. In this regard, it is a better predictor than low Fb levels, acidosis or thrombopenia.<a class="elsevierStyleCrossRef" href="#bib2080"><span class="elsevierStyleSup">217</span></a></p><p id="par0840" class="elsevierStylePara elsevierViewall">Therefore, the detection of hypocalcemia may allow the early detection of patients requiring MT,<a class="elsevierStyleCrossRef" href="#bib1200"><span class="elsevierStyleSup">41</span></a> thereby contributing to secure earlier activation of the MH protocol.</p><p id="par0845" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 45</span></span><a class="elsevierStyleCrossRefs" href="#bib1025"><span class="elsevierStyleSup">6,41,93,216–218</span></a>. <span class="elsevierStyleItalic">It is advisable to monitor plasma calcium levels in bleeding patients (1C).</span></p><p id="par0850" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 46</span></span><a class="elsevierStyleCrossRefs" href="#bib1025"><span class="elsevierStyleSup">6,217,218</span></a>. <span class="elsevierStyleItalic">It is advisable to keep plasma calcium levels within normal limits, administering calcium in the case of hypocalcemia (Ca</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic"><</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">0.9</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mmol/l) (2B)</span>.</p></span><span id="sec0345" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0365">Patients with antiplatelet treatment and anticoagulation</span><p id="par0855" class="elsevierStylePara elsevierViewall">Many patients receive treatment with antiplatelet drugs or anticoagulants. The management of hemorrhage in this setting should include specific guidelines within the global context of the treatment of MH. Some of these aspects have been commented in previous recommendations, though we consider that a specific recommendation for these particular patients is appropriate.</p><p id="par0860" class="elsevierStylePara elsevierViewall">Antiplatelet drugs have many indications, fundamentally in relation to the prevention of arterial thrombosis. A common feature of these agents is their capacity to inhibit platelet aggregation, though this effect is mediated by different mechanisms, and inhibition may be reversible in some cases and irreversible in others.<a class="elsevierStyleCrossRef" href="#bib2090"><span class="elsevierStyleSup">219</span></a> Anticoagulants likewise have a series of indications that include the prevention and treatment of arterial and venous thrombotic phenomena in multiple clinical scenarios. The mechanisms underlying their anticoagulant action are highly varied, ranging from the inhibition of the synthesis of vitamin K-dependent drugs to the antithrombin-mediated or antithrombin-independent inhibition of different coagulation factors.</p><p id="par0865" class="elsevierStylePara elsevierViewall">In general, the mechanisms of action of the antiplatelet drugs and anticoagulants will condition the specific management of hemorrhage in patients who are receiving medications of this kind.<a class="elsevierStyleCrossRef" href="#bib2090"><span class="elsevierStyleSup">219</span></a></p><p id="par0870" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Recommendation 47</span></span><a class="elsevierStyleCrossRefs" href="#bib1460"><span class="elsevierStyleSup">93,219–222</span></a>. <span class="elsevierStyleItalic">Specific management of bleeding is recommended in patients receiving antiplatelet drugs or anticoagulants, conditioned to the particular mechanism of action of each of them (1B).</span></p></span></span></span></span><span id="sec0350" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0370">Funding</span><p id="par0875" class="elsevierStylePara elsevierViewall">This document has been developed thanks to a grant without restrictions from <span class="elsevierStyleGrantSponsor" id="gs1">CSL Behring</span>. However, the document is independent of the financing party, which has not participated in any of the developmental stages of the study.</p></span><span id="sec0355" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0375">Authors’ contribution</span><p id="par0880" class="elsevierStylePara elsevierViewall">All the authors have participated in the development of the present document, thereby meeting the requirements referred to authorship.</p></span><span id="sec0360" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0380">Conflicts of interest</span><p id="par0885" class="elsevierStylePara elsevierViewall">The authors declare the following conflicts of interest related to this document: J.V. Llau: Participation in scientific consultation, training courses or conferences sponsored by Baxter, CSL Behring, Octapharma. F.J. Acosta: Participation in courses organized by CSL Behring and consultant of Edwards. G. Escolar: Participation in scientific consultation, training courses or conferences sponsored by Bayer, Boehringer, BMS-Pfizer, CSL Behring, Novo Nordisk and Terumo BCT. E. Fernandez: Participation in scientific consultation in activities sponsored by CSL Behring and B-Braun. Member of MAB Pulsion. E. Guasch: Participation in conferences sponsored by CSL Behring. P. Marco: Participation in scientific consultation in activities sponsored by Baxter, Octapharma and Novo Nordisk. P. Paniagua: Participation in scientific consultation, training courses or conferences sponsored by CSL Behring. Attendance of congresses financed by Baxter. J.A. Paramo: Participation in conferences sponsored by CSL Behring and Octapharma. M. Quintana: Participation in training courses or conferences sponsored by Baxter, CSL Behring and Octapharma. P. Torrabadella: Participation in scientific consultation in activities sponsored by CSL Behring. Attendance of congresses financed by Orion Pharma.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:12 [ 0 => array:3 [ "identificador" => "xres580639" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec597135" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres580638" "titulo" => "Resumen" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0010" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec597134" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Methodology" ] 6 => array:3 [ "identificador" => "sec0015" "titulo" => "Results and discussion" "secciones" => array:6 [ 0 => array:2 [ "identificador" => "sec0020" "titulo" => "Literature search and development of recommendations" ] 1 => array:3 [ "identificador" => "sec0025" "titulo" => "Definitions" "secciones" => array:2 [ 0 => array:3 [ "identificador" => "sec0030" "titulo" => "Massive hemorrhage" "secciones" => array:4 [ 0 => array:2 [ …2] 1 => array:2 [ …2] 2 => array:2 [ …2] 3 => array:2 [ …2] ] ] 1 => array:3 [ "identificador" => "sec0055" "titulo" => "Massive transfusion" "secciones" => array:3 [ 0 => array:2 [ …2] 1 => array:2 [ …2] 2 => array:2 [ …2] ] ] ] ] 2 => array:3 [ "identificador" => "sec0075" "titulo" => "General interventions" "secciones" => array:5 [ 0 => array:3 [ "identificador" => "sec0080" "titulo" => "Clinical assessment of hemorrhage" "secciones" => array:3 [ 0 => array:2 [ …2] 1 => array:2 [ …2] 2 => array:2 [ …2] ] ] 1 => array:3 [ "identificador" => "sec0100" "titulo" => "Management of hypothermia" "secciones" => array:1 [ 0 => array:2 [ …2] ] ] 2 => array:3 [ "identificador" => "sec0110" "titulo" => "Volume replacement" "secciones" => array:4 [ 0 => array:2 [ …2] 1 => array:2 [ …2] 2 => array:2 [ …2] 3 => array:2 [ …2] ] ] 3 => array:3 [ "identificador" => "sec0135" "titulo" => "Hypotensive resuscitation" "secciones" => array:2 [ 0 => array:2 [ …2] 1 => array:2 [ …2] ] ] 4 => array:3 [ "identificador" => "sec0150" "titulo" => "Damage containment surgery" "secciones" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 3 => array:3 [ "identificador" => "sec0160" "titulo" => "Monitoring" "secciones" => array:2 [ 0 => array:3 [ "identificador" => "sec0165" "titulo" => "Volume monitoring" "secciones" => array:1 [ 0 => array:2 [ …2] ] ] 1 => array:3 [ "identificador" => "sec0175" "titulo" => "Laboratory monitoring" "secciones" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 4 => array:3 [ "identificador" => "sec0185" "titulo" => "Administration of blood components" "secciones" => array:5 [ 0 => array:3 [ "identificador" => "sec0190" "titulo" => "Red cell concentrate" "secciones" => array:1 [ 0 => array:2 [ …2] ] ] 1 => array:3 [ "identificador" => "sec0200" "titulo" => "Optimum treatment ratios" "secciones" => array:1 [ 0 => array:2 [ …2] ] ] 2 => array:3 [ "identificador" => "sec0210" "titulo" => "Fresh plasma" "secciones" => array:1 [ 0 => array:2 [ …2] ] ] 3 => array:3 [ "identificador" => "sec0220" "titulo" => "Platelets" "secciones" => array:4 [ 0 => array:2 [ …2] 1 => array:2 [ …2] 2 => array:2 [ …2] 3 => array:2 [ …2] ] ] 4 => array:3 [ "identificador" => "sec0245" "titulo" => "Other blood components" "secciones" => array:2 [ 0 => array:2 [ …2] 1 => array:2 [ …2] ] ] ] ] 5 => array:3 [ "identificador" => "sec0260" "titulo" => "Administration of hemostatic agents" "secciones" => array:5 [ 0 => array:3 [ "identificador" => "sec0265" "titulo" => "Prothrombin complex" "secciones" => array:3 [ 0 => array:2 [ …2] 1 => array:2 [ …2] 2 => array:2 [ …2] ] ] 1 => array:3 [ "identificador" => "sec0285" "titulo" => "Fibrinogen" "secciones" => array:3 [ 0 => array:2 [ …2] 1 => array:2 [ …2] 2 => array:2 [ …2] ] ] 2 => array:3 [ "identificador" => "sec0305" "titulo" => "Factor VIIa" "secciones" => array:1 [ 0 => array:2 [ …2] ] ] 3 => array:3 [ "identificador" => "sec0315" "titulo" => "Antifibrinolytic agents" "secciones" => array:1 [ 0 => array:2 [ …2] ] ] 4 => array:3 [ "identificador" => "sec0325" "titulo" => "Application of other measures and special situations" "secciones" => array:4 [ 0 => array:2 [ …2] 1 => array:2 [ …2] 2 => array:2 [ …2] 3 => array:2 [ …2] ] ] ] ] ] ] 7 => array:2 [ "identificador" => "sec0350" "titulo" => "Funding" ] 8 => array:2 [ "identificador" => "sec0355" "titulo" => "Authors’ contribution" ] 9 => array:2 [ "identificador" => "sec0360" "titulo" => "Conflicts of interest" ] 10 => array:2 [ "identificador" => "xack195495" "titulo" => "Acknowledgement" ] 11 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2015-02-05" "fechaAceptado" => "2015-05-17" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec597135" "palabras" => array:7 [ 0 => "Consensus" 1 => "Consensus development conference" 2 => "Hemorrhage" 3 => "Shock, hemorrhagic" 4 => "Blood transfusion" 5 => "Blood component transfusion" 6 => "Plasma" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec597134" "palabras" => array:7 [ 0 => "Consenso" 1 => "Conferencia de consenso" 2 => "Hemorragia" 3 => "Choque hemorrágico" 4 => "Transfusión sanguínea" 5 => "Transfusión de componentes sanguíneos" 6 => "Plasma" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Massive haemorrhage is common and often associated with high morbidity and mortality. We perform a systematic review of the literature, with extraction of the recommendations from the existing evidences because of the need for its improvement and the management standardization. From the results we found, we wrote a multidisciplinary consensus document. We begin with the agreement in the definitions of massive haemorrhage and massive transfusion, and we do structured recommendations on their general management (clinical assessment of bleeding, hypothermia management, fluid therapy, hypotensive resuscitation and damage control surgery), blood volume monitoring, blood products transfusion (red blood cells, fresh frozen plasma, platelets and their best transfusion ratio), and administration of hemostatic components (prothrombin complex, fibrinogen, factor VIIa, antifibrinolytic agents).</p></span>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">La hemorragia masiva es una entidad frecuente que se asocia a una elevada morbimortalidad. Ante la necesidad de la implementación y estandarización de su manejo, se realizó una revisión sistemática de la literatura, con extracción de recomendaciones en base a las evidencias existentes. A partir de las mismas se redactó un documento de consenso multidisciplinar. Desde las definiciones de hemorragia masiva y transfusión masiva, se establecen recomendaciones de actuación estructuradas en las medidas generales de manejo de las mismas (valoración clínica de la hemorragia, manejo de la hipotermia, reposición de la volemia, reanimación hipotensiva y cirugía de contención de daños), monitorización de la volemia, administración de hemocomponentes (concentrado de hematíes, plasma fresco, plaquetas, y óptima relación de administración entre ellos), y de hemostáticos (complejo protrombínico, fibrinógeno, factor VIIa, antifibrinolíticos).</p></span>" ] ] "NotaPie" => array:2 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Llau JV, Acosta FJ, Escolar G, Fernández-Mondéjar E, Guasch E, Marco P, et al. Documento multidisciplinar de consenso sobre el manejo de la hemorragia masiva (documento HEMOMAS). Med Intensiva. 2015;39:483–504.</p>" ] 1 => array:3 [ "etiqueta" => "1" "nota" => "<p class="elsevierStyleNotepara" id="npar0010">It must be noted that the derived fibrinogen test is not appropriate for establishing the true fibrinogen concentration. The traditional fibrinogen functional measurement based on the Clauss method is advised.</p>" "identificador" => "fn0005" ] ] "apendice" => array:1 [ 0 => array:1 [ "seccion" => array:1 [ 0 => array:4 [ "apendice" => "<p id="par0900" class="elsevierStylePara elsevierViewall">The following are the supplementary data to this article:<elsevierMultimedia ident="upi0005"></elsevierMultimedia></p>" "etiqueta" => "Appendix A" "titulo" => "Supplementary data" "identificador" => "sec0370" ] ] ] ] "multimedia" => array:2 [ 0 => array:7 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">LE/GR: level of evidence/grade of recommendation.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">No. \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Recommendation \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">LE/GR \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">In evaluating the extent and/or severity of hemorrhage, clinical assessment (mechanism of trauma, anatomical characteristics and initial response) and the application of massive transfusion prediction scales such as the Trauma-Associated Severe Hemorrhage (TASH) are important. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">For the early identification of trauma patients who may benefit from the activation of a massive transfusion protocol it is advisable to use TASH (cutoff score 15), preferably associated to the decrease in clot firmness in rotational thromboelastometry or TEG, if available. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Institutions should develop massive transfusion protocols coordinated on a multidisciplinary basis, with management algorithms fundamented upon scientific evidence. Likewise, informative and training campaigns are recommended, targeted to the teams involved, with periodic evaluation of compliance and effectiveness and compliance. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">The initial assessment should be based on the case history and anamnesis (if possible), and on the sequential determination of BP, HR and SI. The determination of base excess and lactate in arterial blood in these patients may be of help in assessing the more serious cases, fundamentally in the context of polytraumatism. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">The ATLS hemorrhagic shock classification for assessing the extent of hemorrhage remains valid, thanks to its quick application, accessibility and the lack of laboratory test requirements. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">For evaluating the extent of hemorrhage in the pre-hospital setting, it is advisable to use the T-RTS classification (Glasgow Coma Score [GCS], SBP and RF) versus the TS, since it is easier to use and has demonstrated greater assessment capacity. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">In patients with massive hemorrhage, it is advisable to quickly adopt measures for avoiding heat loss and hypothermia, keeping the core temperature above 35<span class="elsevierStyleHsp" style=""></span>°C (1B). Among the measures for avoiding hypothermia, rapid infusion warming systems are recommended for all fluids administered during massive transfusion, with the consideration of extracorporeal warming systems in patients with severe hypothermia and a high risk of cardiac arrest. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1B,2C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Early fluid therapy is recommended in patients with severe hemorrhage and hypotension, preferably using isotonic crystalloids instead of colloids. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1A \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">It is advisable to avoid hypotonic crystalloid solutions such as Ringer lactate in patients with severe traumatic brain injury. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">The administration of hypertonic solutions should be evaluated in patients with severe traumatic brain injury (2B) and in patients with penetrating trunk injuries (2C). \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2B-2C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">11 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">If the clinician decides to administer colloids, it is advisable to use a dose within the limits established for each solution and patient. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1B \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">In patients with MH, the early administration of blood products (including RCC, fresh plasma [FP], platelets and fibrinogen) is advised, along with simultaneous correction of the hypovolemia. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1B \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">It is advisable for initial fluid replacement in patients with MH to be based on the estimated blood loss and hemodynamic response to fluid administration. The application of a “hypotensive resuscitation strategy” is recommended until the cause of bleeding has been controlled, provided the patient does not suffer traumatic brain injury. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">14 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">In trauma patients with hemorrhage and hypotension, and without traumatic brain injury, a systolic blood pressure target of between 80 and 90<span class="elsevierStyleHsp" style=""></span>mmHg is recommended until the cause of bleeding has been controlled. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">In trauma patients with severe TBI it is advisable to maintain a systolic blood pressure of at least 110<span class="elsevierStyleHsp" style=""></span>mmHg or a mean blood pressure of at least 80<span class="elsevierStyleHsp" style=""></span>mmHg. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">It is suggested that the use of vasopressors such as epinephrine or norepinephrine may be an option for maintaining blood pressure in the absence of an adequate response to fluid therapy. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">17 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Application of the concept of damage containment surgery is recommended in trauma patients requiring surgical control of their injuries and who present coagulopathy with incoercible bleeding accompanied by acidosis and/or hypothermia. Likewise, this strategy should be used in the case of anatomically very complex injuries or injuries of difficult access and which require prolonged surgical times. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1B \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">18 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">The use of dynamic variables such as SVV and PPV, instead of static variables, is advised for predicting response to the administration of fluids in patients with severe hemorrhage subjected to controlled mechanical ventilation and with a normal cardiac rhythm who fail to respond to initial resuscitation therapy. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1B \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">19 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">The early and serial determination of hematological parameters such as hemoglobin, lactate, base excess (both arterial and venous) and coagulation tests (prothrombin time, INR, activated partial thromboplastin time [aPTT], fibrinogen and platelets) is advised in order to ensure the early detection of coagulopathy. These tests appear to yield altered results in early stages and are good prognostic indicators in these patients. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">20 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">The use of viscoelastic tests such as ROTEM<span class="elsevierStyleSup">®</span> or TEG is recommended, since they can help detect, control and orientate the treatment of coagulopathy associated to acute hemorrhage, particularly in the presence of the lethal triad (hypothermia, acidosis and coagulopathy). \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">21 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Transfusion protocols in massive hemorrhage should function with an alarm system defined by the hemotherapy commission of each individual hospital, as a consensus-based interdisciplinary protocol, with period assessment of its efficacy and safety. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">22 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">In the context of massive hemorrhage, it is advisable to consider the early transfusion of red cell concentrates. As an orientation in this regard, the evolution of both clinical parameters (BP, HR, SI) and laboratory values (hemoglobin, lactate, base excess [BE]) should be taken into account, avoiding transfusions based on isolated determinations, and in all cases individualizing the clinical situation of the patient. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1B \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">23 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">It is advisable to manage MH with a high proportion of fresh plasma and platelets in relation to the red cell concentrates, since improved results appear to be obtained, particularly in polytraumatized patients (improvements in survival and in the prevention and control of coagulopathy). \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">In the context of massive hemorrhage, it is advisable to start the administration of fresh plasma early in order to prevent and/or treat coagulopathy. The recommended volume of fresh plasma depends on clinical (control of bleeding) and/or laboratory test parameters (thromboelastographic and/or standard coagulation values). \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">25 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">The administration of platelet concentrates (PC) is recommended for maintaining a platelet count above 50<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">9</span>/l in trauma patients. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">26 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Platelet transfusions are recommended for maintaining counts above 75<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">9</span>/l in patients with active bleeding when hemorrhage does not cease in the presence of counts of 50<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">9</span>/l. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">27 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">The maintenance of platelet counts above 100<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">9</span>/l is advised in patients with massive bleeding and traumatic brain injury. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">28 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">An initial dose of 4–8 PC (equivalent to 1–2 pools) is recommended. The administration frequency should be adjusted according to the persistence of hemorrhage, the counts reached with the starting dose, and the patient response to other measures adopted to control the bleeding. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">29 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">The systematic use of albumin in patients with massive hemorrhage is not advised. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">30 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">The use of topical hemostatic agents is recommended in combination with conventional measures in bleeding associated to different surgical procedures. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1B \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">31 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">In the context of massive hemorrhage, the use of prothrombin complex concentrate is recommended in patients receiving treatment with anti-vitamin K anticoagulants for the rapid reversal of their effects. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">32 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">In the context of massive hemorrhage, in patients not receiving treatment with oral anti-vitamin K anticoagulants, the use of prothrombin complex concentrate as first option for the correction of coagulopathy is not recommended. It may be used in selected patients, depending on the urgency of treatment and the availability of FP. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">33 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">It is advisable to regularly determine plasma fibrinogen using a coagulometric (Clauss) or viscoelastometric method (Fibtem with ROTEM<span class="elsevierStyleSup">®</span> or Functional Fibrinogen with TEG), in order to ensure the effectiveness of the prothrombin complex concentrate, since a fibrinogen level of <2<span class="elsevierStyleHsp" style=""></span>g/l in this clinical situation does not guarantee good hemostasis. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">34 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">It is advisable to administer intravenous vitamin K (10<span class="elsevierStyleHsp" style=""></span>mg) in patients with massive hemorrhage treated with anti-vitamin K anticoagulants (1C). However, it should not be administered in a similar context in those patients anticoagulated with a direct action oral anticoagulant. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">35 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">It is not advisable to use activated prothrombin complex in massive hemorrhage, since it is specifically indicated in congenital hemophilia with inhibitor and acquired hemophilia. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">36 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Caution is recommended when using prothrombin complexes in patients with life-threatening massive hemorrhage or who must undergo surgery without delay and are at a high risk of suffering thrombosis. A maximum dose of 20–25<span class="elsevierStyleHsp" style=""></span>IU/kg is advised. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">37 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">The determination of fibrinogen using the Clauss method or FIBTEM in ROTEM<span class="elsevierStyleSup">®</span> or Functional Fibrinogen in TEG is recommended for diagnostic purposes, or when decisions referred to the clinical management of patients with massive hemorrhage must be made. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">38 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Since adequate clot firmness only appears to be achieved from a plasma Fb concentration of over 2<span class="elsevierStyleHsp" style=""></span>g/l, it is advisable to administer Fb when this threshold is not reached as determined by the Clauss method, FIBTEM-MCF in ROTEM<span class="elsevierStyleSup">®</span> is under 7<span class="elsevierStyleHsp" style=""></span>mm or, by equivalence, the maximum FLEV amplitude is under 10<span class="elsevierStyleHsp" style=""></span>mm. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">39 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">A starting dose of 25–50<span class="elsevierStyleHsp" style=""></span>mg/kg of fibrinogen concentrate is recommended when the advised plasma fibrinogen threshold is not reached. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">40 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Factor VIIa is not recommended as a routine first level option in the treatment of massive hemorrhage. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1B \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">41 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">The early administration (in the first 3<span class="elsevierStyleHsp" style=""></span>h) of tranexamic acid is advised in patients with massive hemorrhage secondary to trauma. The recommended starting dose is 1<span class="elsevierStyleHsp" style=""></span>g in 10<span class="elsevierStyleHsp" style=""></span>min, followed by an intravenous infusion of 1<span class="elsevierStyleHsp" style=""></span>g in 8<span class="elsevierStyleHsp" style=""></span>h. Later administration (over 3<span class="elsevierStyleHsp" style=""></span>h after trauma) is not advised, due to the increase in mortality associated to bleeding. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1A \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">42 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">The evaluation of measures without transfusion, such as angioembolization or the use of endovascular procedures, is recommended for the treatment of massive hemorrhage in selected patients, provided such measures are available. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1B \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">43 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Evaluation of the administration of desmopressin (0.3<span class="elsevierStyleHsp" style=""></span>μg/kg) is advised in bleeding patients Von Willebrand disease. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">44 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Evaluation of the administration of desmopressin (0.3<span class="elsevierStyleHsp" style=""></span>μg/kg) is advised in uremic bleeding patients or those taking aspirin. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">45 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">It is advisable to monitor plasma calcium levels in bleeding patients. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">46 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">It is advisable to keep plasma calcium levels within normal limits, administering calcium in the case of hypocalcemia (Ca<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.9<span class="elsevierStyleHsp" style=""></span>mmol/l). \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2B \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">47 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Specific management of bleeding is recommended in patients receiving antiplatelet drugs or anticoagulants, conditioned to the particular mechanism of action of each of them. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1B \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab947389.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Summary of the recommendations.</p>" ] ] 1 => array:5 [ "identificador" => "upi0005" "tipo" => "MULTIMEDIAECOMPONENTE" "mostrarFloat" => false "mostrarDisplay" => true "Ecomponente" => array:2 [ "fichero" => "mmc1.docx" "ficheroTamanyo" => 112146 ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:222 [ 0 => array:3 [ "identificador" => "bib1000" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 1 => array:3 [ "identificador" => "bib1005" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 2 => array:3 [ "identificador" => "bib1010" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 3 => array:3 [ "identificador" => "bib1015" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 4 => array:3 [ "identificador" => "bib1020" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 5 => array:3 [ "identificador" => "bib1025" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 6 => array:3 [ "identificador" => "bib1030" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 7 => array:3 [ "identificador" => "bib1035" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 8 => array:3 [ "identificador" => "bib1040" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 9 => array:3 [ "identificador" => "bib1045" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 10 => array:3 [ "identificador" => "bib1050" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 11 => array:3 [ "identificador" => "bib1055" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 12 => array:3 [ "identificador" => "bib1060" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 13 => array:3 [ "identificador" => "bib1065" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 14 => array:3 [ "identificador" => "bib1070" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 15 => array:3 [ "identificador" => "bib1075" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 16 => array:3 [ "identificador" => "bib1080" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 17 => array:3 [ "identificador" => "bib1085" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 18 => array:3 [ "identificador" => "bib1090" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 19 => array:3 [ "identificador" => "bib1095" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 20 => array:3 [ "identificador" => "bib1100" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 21 => array:3 [ "identificador" => "bib1105" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 22 => array:3 [ "identificador" => "bib1110" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 23 => array:3 [ "identificador" => "bib1115" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 24 => array:3 [ "identificador" => "bib1120" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 25 => array:3 [ "identificador" => "bib1125" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 26 => array:3 [ "identificador" => "bib1130" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 27 => array:3 [ "identificador" => "bib1135" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 28 => array:3 [ "identificador" => "bib1140" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 29 => array:3 [ "identificador" => "bib1145" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 30 => array:3 [ "identificador" => "bib1150" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 31 => array:3 [ "identificador" => "bib1155" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 32 => array:3 [ "identificador" => "bib1160" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 33 => array:3 [ "identificador" => "bib1165" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 34 => array:3 [ "identificador" => "bib1170" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 35 => array:3 [ "identificador" => "bib1175" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 36 => array:3 [ "identificador" => "bib1180" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 37 => array:3 [ "identificador" => "bib1185" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 38 => array:3 [ "identificador" => "bib1190" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 39 => array:3 [ "identificador" => "bib1195" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 40 => array:3 [ "identificador" => "bib1200" "etiqueta" => "41" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 41 => array:3 [ "identificador" => "bib1205" "etiqueta" => "42" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 42 => array:3 [ "identificador" => "bib1210" "etiqueta" => "43" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 43 => array:3 [ "identificador" => "bib1215" "etiqueta" => "44" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 44 => array:3 [ "identificador" => "bib1220" "etiqueta" => "45" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 45 => array:3 [ "identificador" => "bib1225" "etiqueta" => "46" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 46 => array:3 [ "identificador" => "bib1230" "etiqueta" => "47" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 47 => array:3 [ "identificador" => "bib1235" "etiqueta" => "48" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 48 => array:3 [ "identificador" => "bib1240" "etiqueta" => "49" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 49 => array:3 [ "identificador" => "bib1245" "etiqueta" => "50" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 50 => array:3 [ "identificador" => "bib1250" "etiqueta" => "51" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 51 => array:3 [ "identificador" => "bib1255" "etiqueta" => "52" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 52 => array:3 [ "identificador" => "bib1260" "etiqueta" => "53" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 53 => array:3 [ "identificador" => "bib1265" "etiqueta" => "54" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 54 => array:3 [ "identificador" => "bib1270" "etiqueta" => "55" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 55 => array:3 [ "identificador" => "bib1275" "etiqueta" => "56" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 56 => array:3 [ "identificador" => "bib1280" "etiqueta" => "57" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 57 => array:3 [ "identificador" => "bib1285" "etiqueta" => "58" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 58 => array:3 [ "identificador" => "bib1290" "etiqueta" => "59" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 59 => array:3 [ "identificador" => "bib1295" "etiqueta" => "60" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 60 => array:3 [ "identificador" => "bib1300" "etiqueta" => "61" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 61 => array:3 [ "identificador" => "bib1305" "etiqueta" => "62" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 62 => array:3 [ "identificador" => "bib1310" "etiqueta" => "63" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 63 => array:3 [ "identificador" => "bib1315" "etiqueta" => "64" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 64 => array:3 [ "identificador" => "bib1320" "etiqueta" => "65" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 65 => array:3 [ "identificador" => "bib1325" "etiqueta" => "66" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 66 => array:3 [ "identificador" => "bib1330" "etiqueta" => "67" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 67 => array:3 [ "identificador" => "bib1335" "etiqueta" => "68" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 68 => array:3 [ "identificador" => "bib1340" "etiqueta" => "69" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 69 => array:3 [ "identificador" => "bib1345" "etiqueta" => "70" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 70 => array:3 [ "identificador" => "bib1350" "etiqueta" => "71" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 71 => array:3 [ "identificador" => "bib1355" "etiqueta" => "72" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 72 => array:3 [ "identificador" => "bib1360" "etiqueta" => "73" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 73 => array:3 [ "identificador" => "bib1365" "etiqueta" => "74" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 74 => array:3 [ "identificador" => "bib1370" "etiqueta" => "75" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 75 => array:3 [ "identificador" => "bib1375" "etiqueta" => "76" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 76 => array:3 [ "identificador" => "bib1380" "etiqueta" => "77" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 77 => array:3 [ "identificador" => "bib1385" "etiqueta" => "78" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 78 => array:3 [ "identificador" => "bib1390" "etiqueta" => "79" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 79 => array:3 [ "identificador" => "bib1395" "etiqueta" => "80" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 80 => array:3 [ "identificador" => "bib1400" "etiqueta" => "81" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 81 => array:3 [ "identificador" => "bib1405" "etiqueta" => "82" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 82 => array:3 [ "identificador" => "bib1410" "etiqueta" => "83" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 83 => array:3 [ "identificador" => "bib1415" "etiqueta" => "84" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 84 => array:3 [ "identificador" => "bib1420" "etiqueta" => "85" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 85 => array:3 [ "identificador" => "bib1425" "etiqueta" => "86" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 86 => array:3 [ "identificador" => "bib1430" "etiqueta" => "87" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 87 => array:3 [ "identificador" => "bib1435" "etiqueta" => "88" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 88 => array:3 [ "identificador" => "bib1440" "etiqueta" => "89" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 89 => array:3 [ "identificador" => "bib1445" "etiqueta" => "90" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 90 => array:3 [ "identificador" => "bib1450" "etiqueta" => "91" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 91 => array:3 [ "identificador" => "bib1455" "etiqueta" => "92" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 92 => array:3 [ "identificador" => "bib1460" "etiqueta" => "93" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 93 => array:3 [ "identificador" => "bib1465" "etiqueta" => "94" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 94 => array:3 [ "identificador" => "bib1470" "etiqueta" => "95" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 95 => array:3 [ "identificador" => "bib1475" "etiqueta" => "96" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 96 => array:3 [ "identificador" => "bib1480" "etiqueta" => "97" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 97 => array:3 [ "identificador" => "bib1485" "etiqueta" => "98" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 98 => array:3 [ "identificador" => "bib1490" "etiqueta" => "99" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 99 => array:3 [ "identificador" => "bib1495" "etiqueta" => "100" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 100 => array:3 [ "identificador" => "bib1500" "etiqueta" => "101" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 101 => array:3 [ "identificador" => "bib1505" "etiqueta" => "102" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 102 => array:3 [ "identificador" => "bib1510" "etiqueta" => "103" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 103 => array:3 [ "identificador" => "bib1515" "etiqueta" => "104" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 104 => array:3 [ "identificador" => "bib1520" "etiqueta" => "105" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 105 => array:3 [ "identificador" => "bib1525" "etiqueta" => "106" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 106 => array:3 [ "identificador" => "bib1530" "etiqueta" => "107" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 107 => array:3 [ "identificador" => "bib1535" "etiqueta" => "108" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 108 => array:3 [ "identificador" => "bib1540" "etiqueta" => "109" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 109 => array:3 [ "identificador" => "bib1545" "etiqueta" => "110" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 110 => array:3 [ "identificador" => "bib1550" "etiqueta" => "111" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 111 => array:3 [ "identificador" => "bib1555" "etiqueta" => "112" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 112 => array:3 [ "identificador" => "bib1560" "etiqueta" => "113" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 113 => array:3 [ "identificador" => "bib1565" "etiqueta" => "114" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 114 => array:3 [ "identificador" => "bib1570" "etiqueta" => "115" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:2 [ …2] ] ] ] ] 115 => array:3 [ "identificador" => "bib1575" "etiqueta" => "116" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 116 => array:3 [ "identificador" => "bib1580" "etiqueta" => "117" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ 0 => array:1 [ …1] ] ] ] ] 117 => array:3 [ "identificador" => "bib1585" "etiqueta" => "118" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ …2] ] "host" => array:1 [ …1] ] ] ] 118 => array:3 [ "identificador" => "bib1590" "etiqueta" => "119" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 119 => array:3 [ "identificador" => "bib1595" "etiqueta" => "120" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 120 => array:3 [ "identificador" => "bib1600" "etiqueta" => "121" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 121 => array:3 [ "identificador" => "bib1605" "etiqueta" => "122" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 122 => array:3 [ "identificador" => "bib1610" "etiqueta" => "123" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 123 => array:3 [ "identificador" => "bib1615" "etiqueta" => "124" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 124 => array:3 [ "identificador" => "bib1620" "etiqueta" => "125" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 125 => array:3 [ "identificador" => "bib1625" "etiqueta" => "126" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 126 => array:3 [ "identificador" => "bib1630" "etiqueta" => "127" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 127 => array:3 [ "identificador" => "bib1635" "etiqueta" => "128" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 128 => array:3 [ "identificador" => "bib1640" "etiqueta" => "129" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 129 => array:3 [ "identificador" => "bib1645" "etiqueta" => "130" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 130 => array:3 [ "identificador" => "bib1650" "etiqueta" => "131" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 131 => array:3 [ "identificador" => "bib1655" "etiqueta" => "132" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 132 => array:3 [ "identificador" => "bib1660" "etiqueta" => "133" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 133 => array:3 [ "identificador" => "bib1665" "etiqueta" => "134" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 134 => array:3 [ "identificador" => "bib1670" "etiqueta" => "135" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 135 => array:3 [ "identificador" => "bib1675" "etiqueta" => "136" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 136 => array:3 [ "identificador" => "bib1680" "etiqueta" => "137" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 137 => array:3 [ "identificador" => "bib1685" "etiqueta" => "138" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 138 => array:3 [ "identificador" => "bib1690" "etiqueta" => "139" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 139 => array:3 [ "identificador" => "bib1695" "etiqueta" => "140" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 140 => array:3 [ "identificador" => "bib1700" "etiqueta" => "141" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 141 => array:3 [ "identificador" => "bib1705" "etiqueta" => "142" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 142 => array:3 [ "identificador" => "bib1710" "etiqueta" => "143" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 143 => array:3 [ "identificador" => "bib1715" "etiqueta" => "144" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 144 => array:3 [ "identificador" => "bib1720" "etiqueta" => "145" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 145 => array:3 [ "identificador" => "bib1725" "etiqueta" => "146" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 146 => array:3 [ "identificador" => "bib1730" "etiqueta" => "147" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 147 => array:3 [ "identificador" => "bib1735" "etiqueta" => "148" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 148 => array:3 [ "identificador" => "bib1740" "etiqueta" => "149" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 149 => array:3 [ "identificador" => "bib1745" "etiqueta" => "150" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 150 => array:3 [ "identificador" => "bib1750" "etiqueta" => "151" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 151 => array:3 [ "identificador" => "bib1755" "etiqueta" => "152" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 152 => array:3 [ "identificador" => "bib1760" "etiqueta" => "153" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 153 => array:3 [ "identificador" => "bib1765" "etiqueta" => "154" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 154 => array:3 [ "identificador" => "bib1770" "etiqueta" => "155" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 155 => array:3 [ "identificador" => "bib1775" "etiqueta" => "156" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 156 => array:3 [ "identificador" => "bib1780" "etiqueta" => "157" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 157 => array:3 [ "identificador" => "bib1785" "etiqueta" => "158" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 158 => array:3 [ "identificador" => "bib1790" "etiqueta" => "159" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 159 => array:3 [ "identificador" => "bib1795" "etiqueta" => "160" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 160 => array:3 [ "identificador" => "bib1800" "etiqueta" => "161" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 161 => array:3 [ "identificador" => "bib1805" "etiqueta" => "162" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 162 => array:3 [ "identificador" => "bib1810" "etiqueta" => "163" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 163 => array:3 [ "identificador" => "bib1815" "etiqueta" => "164" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 164 => array:3 [ "identificador" => "bib1820" "etiqueta" => "165" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 165 => array:3 [ "identificador" => "bib1825" "etiqueta" => "166" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 166 => array:3 [ "identificador" => "bib1830" "etiqueta" => "167" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 167 => array:3 [ "identificador" => "bib1835" "etiqueta" => "168" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 168 => array:3 [ "identificador" => "bib1840" "etiqueta" => "169" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 169 => array:3 [ "identificador" => "bib1845" "etiqueta" => "170" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 170 => array:3 [ "identificador" => "bib1850" "etiqueta" => "171" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 171 => array:3 [ "identificador" => "bib1855" "etiqueta" => "172" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 172 => array:3 [ "identificador" => "bib1860" "etiqueta" => "173" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 173 => array:3 [ "identificador" => "bib1865" "etiqueta" => "174" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 174 => array:3 [ "identificador" => "bib1870" "etiqueta" => "175" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 175 => array:3 [ "identificador" => "bib1875" "etiqueta" => "176" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 176 => array:3 [ "identificador" => "bib1880" "etiqueta" => "177" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 177 => array:3 [ "identificador" => "bib1885" "etiqueta" => "178" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 178 => array:3 [ "identificador" => "bib1890" "etiqueta" => "179" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 179 => array:3 [ "identificador" => "bib1895" "etiqueta" => "180" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 180 => array:3 [ "identificador" => "bib1900" "etiqueta" => "181" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 181 => array:3 [ "identificador" => "bib1905" "etiqueta" => "182" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 182 => array:3 [ "identificador" => "bib1910" "etiqueta" => "183" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 183 => array:3 [ "identificador" => "bib1915" "etiqueta" => "184" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 184 => array:3 [ "identificador" => "bib1920" "etiqueta" => "185" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 185 => array:3 [ "identificador" => "bib1925" "etiqueta" => "186" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 186 => array:3 [ "identificador" => "bib1930" "etiqueta" => "187" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 187 => array:3 [ "identificador" => "bib1935" "etiqueta" => "188" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 188 => array:3 [ "identificador" => "bib1940" "etiqueta" => "189" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 189 => array:3 [ "identificador" => "bib1945" "etiqueta" => "190" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 190 => array:3 [ "identificador" => "bib1950" "etiqueta" => "191" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 191 => array:3 [ "identificador" => "bib1955" "etiqueta" => "192" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "EMA, Summary of product characteristics [consulted 12.03.14]. Avaialable at: <a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a>." ] ] ] 192 => array:3 [ "identificador" => "bib1960" "etiqueta" => "193" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 193 => array:3 [ "identificador" => "bib1965" "etiqueta" => "194" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 194 => array:3 [ "identificador" => "bib1970" "etiqueta" => "195" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 195 => array:3 [ "identificador" => "bib1975" "etiqueta" => "196" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 196 => array:3 [ "identificador" => "bib1980" "etiqueta" => "197" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 197 => array:3 [ "identificador" => "bib1985" "etiqueta" => "198" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 198 => array:3 [ "identificador" => "bib1990" "etiqueta" => "199" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 199 => array:3 [ "identificador" => "bib1995" "etiqueta" => "200" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 200 => array:3 [ "identificador" => "bib2000" "etiqueta" => "201" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 201 => array:3 [ "identificador" => "bib2005" "etiqueta" => "202" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 202 => array:3 [ "identificador" => "bib2010" "etiqueta" => "203" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 203 => array:3 [ "identificador" => "bib2015" "etiqueta" => "204" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 204 => array:3 [ "identificador" => "bib2020" "etiqueta" => "205" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 205 => array:3 [ "identificador" => "bib2025" "etiqueta" => "206" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 206 => array:3 [ "identificador" => "bib2030" "etiqueta" => "207" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 207 => array:3 [ "identificador" => "bib2035" "etiqueta" => "208" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 208 => array:3 [ "identificador" => "bib2040" "etiqueta" => "209" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 209 => array:3 [ "identificador" => "bib2045" "etiqueta" => "210" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 210 => array:3 [ "identificador" => "bib2050" "etiqueta" => "211" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 211 => array:3 [ "identificador" => "bib2055" "etiqueta" => "212" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 212 => array:3 [ "identificador" => "bib2060" "etiqueta" => "213" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 213 => array:3 [ "identificador" => "bib2065" "etiqueta" => "214" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 214 => array:3 [ "identificador" => "bib2070" "etiqueta" => "215" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 215 => array:3 [ "identificador" => "bib2075" "etiqueta" => "216" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 216 => array:3 [ "identificador" => "bib2080" "etiqueta" => "217" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 217 => array:3 [ "identificador" => "bib2085" "etiqueta" => "218" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 218 => array:3 [ "identificador" => "bib2090" "etiqueta" => "219" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 219 => array:3 [ "identificador" => "bib2095" "etiqueta" => "220" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 220 => array:3 [ "identificador" => "bib2100" "etiqueta" => "221" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] 221 => array:3 [ "identificador" => "bib2105" "etiqueta" => "222" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ …1] "host" => array:1 [ …1] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack195495" "titulo" => "Acknowledgement" "texto" => "<p id="par0890" class="elsevierStylePara elsevierViewall">Thanks are due to GOC Networking for logistic support.</p>" "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/21735727/0000003900000008/v1_201511200058/S2173572715000636/v1_201511200058/en/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/21735727/0000003900000008/v1_201511200058/S2173572715000636/v1_201511200058/en/main.pdf?idApp=WMIE&text.app=https://medintensiva.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173572715000636?idApp=WMIE" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 18 | 12 | 30 |
2024 October | 104 | 50 | 154 |
2024 September | 100 | 41 | 141 |
2024 August | 94 | 57 | 151 |
2024 July | 107 | 68 | 175 |
2024 June | 96 | 75 | 171 |
2024 May | 83 | 51 | 134 |
2024 April | 78 | 46 | 124 |
2024 March | 79 | 45 | 124 |
2024 February | 66 | 61 | 127 |
2024 January | 62 | 42 | 104 |
2023 December | 69 | 38 | 107 |
2023 November | 74 | 80 | 154 |
2023 October | 95 | 54 | 149 |
2023 September | 81 | 50 | 131 |
2023 August | 66 | 26 | 92 |
2023 July | 72 | 27 | 99 |
2023 June | 95 | 38 | 133 |
2023 May | 80 | 50 | 130 |
2023 April | 77 | 41 | 118 |
2023 March | 123 | 41 | 164 |
2023 February | 86 | 46 | 132 |
2023 January | 65 | 39 | 104 |
2022 December | 73 | 36 | 109 |
2022 November | 86 | 47 | 133 |
2022 October | 101 | 58 | 159 |
2022 September | 101 | 52 | 153 |
2022 August | 106 | 58 | 164 |
2022 July | 90 | 57 | 147 |
2022 June | 92 | 46 | 138 |
2022 May | 67 | 61 | 128 |
2022 April | 77 | 62 | 139 |
2022 March | 82 | 66 | 148 |
2022 February | 65 | 58 | 123 |
2022 January | 56 | 31 | 87 |
2021 December | 66 | 60 | 126 |
2021 November | 64 | 53 | 117 |
2021 October | 96 | 83 | 179 |
2021 September | 68 | 42 | 110 |
2021 August | 85 | 56 | 141 |
2021 July | 63 | 40 | 103 |
2021 June | 67 | 49 | 116 |
2021 May | 86 | 65 | 151 |
2021 April | 244 | 169 | 413 |
2021 March | 112 | 52 | 164 |
2021 February | 91 | 46 | 137 |
2021 January | 91 | 30 | 121 |
2020 December | 75 | 24 | 99 |
2020 November | 61 | 35 | 96 |
2020 October | 80 | 41 | 121 |
2020 September | 84 | 39 | 123 |
2020 August | 62 | 16 | 78 |
2020 July | 70 | 45 | 115 |
2020 June | 87 | 36 | 123 |
2020 May | 73 | 37 | 110 |
2020 April | 80 | 31 | 111 |
2020 March | 66 | 37 | 103 |
2020 February | 156 | 56 | 212 |
2020 January | 102 | 49 | 151 |
2019 December | 100 | 42 | 142 |
2019 November | 99 | 55 | 154 |
2019 October | 119 | 72 | 191 |
2019 September | 66 | 51 | 117 |
2019 August | 54 | 67 | 121 |
2019 July | 68 | 49 | 117 |
2019 June | 55 | 28 | 83 |
2019 May | 77 | 56 | 133 |
2019 April | 90 | 44 | 134 |
2019 March | 41 | 61 | 102 |
2019 February | 39 | 41 | 80 |
2019 January | 43 | 32 | 75 |
2018 December | 82 | 62 | 144 |
2018 November | 433 | 57 | 490 |
2018 October | 596 | 40 | 636 |
2018 September | 93 | 24 | 117 |
2018 August | 48 | 15 | 63 |
2018 July | 32 | 16 | 48 |
2018 June | 55 | 23 | 78 |
2018 May | 32 | 13 | 45 |
2018 April | 37 | 20 | 57 |
2018 March | 42 | 18 | 60 |
2018 February | 29 | 18 | 47 |
2018 January | 36 | 17 | 53 |
2017 December | 40 | 12 | 52 |
2017 November | 46 | 19 | 65 |
2017 October | 48 | 21 | 69 |
2017 September | 28 | 29 | 57 |
2017 August | 30 | 21 | 51 |
2017 July | 34 | 20 | 54 |
2017 June | 53 | 26 | 79 |
2017 May | 58 | 25 | 83 |
2017 April | 61 | 15 | 76 |
2017 March | 25 | 9 | 34 |
2017 February | 12 | 7 | 19 |
2017 January | 7 | 7 | 14 |
2016 December | 35 | 13 | 48 |
2016 November | 51 | 25 | 76 |
2016 October | 54 | 31 | 85 |
2016 September | 58 | 18 | 76 |
2016 August | 46 | 19 | 65 |
2016 July | 34 | 10 | 44 |